Transferosomal Formulation of Rotigotine Hcl and Rasagiline Mesylate: a Step Towards Minimally Invasive Parkinson's Disease Therapy

Transferosomal Formulation of Rotigotine Hcl and Rasagiline Mesylate: a Step Towards Minimally Invasive Parkinson's Disease Therapy | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Transferosomal Formulation of Rotigotine Hcl and Rasagiline Mesylate: a Step Towards Minimally Invasive Parkinson's Disease Therapy Shivani Patel, Lalit Lata Jha, Riya Patel This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4761605/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background Parkinson’s disease (PD) is a clinical syndrome with symptoms like rest tremor, rigidity, bradykinesia, instability of posture, and a diversity of other motor and non-motor symptoms. The disease study prognosis is that the number of PD cases will double from 7 million in 2015 to 13 million in 2040. The majority of the treatments for PD include surgery and medications. The drawback of available treatments is that they are invasive and lead to systemic side effects. Aim This research aims to prepare transferosome patches of both drugs of different BCS classes, Rotigotine HCL (RTG) BCS class II and Rasagiline mesylate (RSM) BCS class III, and evaluate them with different parameters to check the synergistic effects of both drugs with the in vivo study. Method A transferosomal patch of drugs was prepared by thin film hydration followed by a homogenization casting method. The patches were optimized with the central composite design. The optimized batch was further evaluated with various parameters like thickness, folding endurance, drug content, in vitro drug release, ex vivo drug permeation, pharmacokinetics, and in vivo skin irritancy studies. Results After the evaluation of the drugs, loaded transferosome patches show good tensile strength; drug content was found within the range in both cases and shows the controlled release of the drugs; pharmacokinetic studies show the quick onset of action; and in vivo, skin irritancy results show no damage to the tissue at the site of action. Conclusion From the results, it has been observed that the prepared transferosome patch can treat PD with the synergistic effects of the drugs via the topical route. Rotigotine HCL Rasagiline mesylate Transferosomes Patches Parkinson's Disease Combination therapy Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Figure 8 Figure 9 Figure 10 Figure 11 Figure 12 1 Introduction Parkinson’s disease (PD) is a clinical syndrome that was introduced by James Parkinson in 1817. The disease exhibits essential symptoms like rest tremors, rigidity, bradykinesia, instability of posture, and a diversity of other motor and non-motor symptoms[ 1 ]. The scientific community is paying more attention to age-related disorders like PD as the world's population ages and lives longer. The fastest-growing of these neurological illnesses is PD, which is currently the main cause of disability in the world. A potential "PD Epidemic" is suggested by the World Burden of Disease Study's prognosis that the number of PD cases will double from 7 million in 2015 to 13 million in 2040[ 2 ]. The majority of the treatments for PD include surgery and medications. The surgical approach includes deep brain stimulation, focused ultrasound, and cell replacement therapies that are invasive, while the medication includes levodopa, which is combined with carbidopa or benderizine, aromatic acid decarboxylase inhibitors, an anticholinergics amantadine, MAOIs, COMTIs, dopamine agonists [ 3 ][ 4 ]. Adverse effects of the medication include nausea and vomiting, orthostatic hypotension, sedation, confusion, sleep disturbance, hallucinations, and dyskinesias. It should not be used in patients with renal impairment[ 5 ]. Rotigotine HCL (RTG) is a dopamine receptor agonist approved for the treatment of idiopathic PD in several countries. The pharmacologically active form of RTG is its unconjugated parent drug[ 6 ], which binds to dopamine receptors to produce its effects, and Rasagiline mesylate (RSM), an irreversible propargylamine-based MAO B inhibitor, was approved for the treatment of idiopathic Parkinson's disease in May 2006; the US Federal Drug Administration (FDA) followed suit[ 7 ]. RSM is an irreversible inhibitor of MAO-B that selectively binds to and permanently deactivates this enzyme, leading to increased dopamine levels in the striatum and improved Parkinson's symptoms. Both thugs are from BCS classes II and III, respectively[ 8 ].Many researcher prepared formulation by altering the route of administration and changing formulation to get better effect[ 9 – 16 ]. The RSM is administered via a transdermal patch and is available in different strengths. Compared to oral therapy, transdermal delivery eliminates variables affecting gut absorption and bypasses the first-pass effects of the liver[ 17 ]. It provides continuous delivery, maintaining stable plasma drug concentrations over 24 hours with just one daily application. Transdermal delivery is also useful in perioperative and intensive care settings. On the other hand, RSM is available in oral tablet form with different strengths. Several factors, including the presence of hepatic first-pass metabolism, negative side effects, the rejection of invasive treatments, and poor patient compliance, make it difficult to obtain an effective, successful therapeutic therapy. Hence, numerous drug delivery methods have been researched and developed over the years to address these issues[ 3 ]. Transdermal delivery systems, which are minimally invasive and have no first-pass effects, are one intriguing strategy. Yet it is important to address the skin's barrier function, which hinders or stops medicinal substances from being delivered transdermally[ 18 ]. The problem has been solved by employing nanoencapsulation with lipidic nanosystems, such as liposomes, SLN, NLC, etc[ 19 – 23 ]. These carriers promote medication delivery through the skin: attachment to fusion with the stratum corneum's Shahd matrix, which increases drug partitioning into the skin, and lipid exchange between the liposomal membrane and cell membrane[ 24 ] which makes it easier for the drug to diffuse across membranes, but the drawbacks that are also present in such lipidic carriers are inadequate hydrophilic drug encapsulation efficiency, an unstable leaky behavior, and a brief half-life. The drug is then transferred directly from the vesicles to the skin surface. The newly introduced cutting-edge medication carriers for skin are called transferosomes, which can transport large molecules through intact mammalian tissues. A transferosome can instinctively penetrate skin and transport drugs from the application to the target area. The transferosome carriers are composed of hydrophilic and hydrophobic moieties, making them a unique class of drug delivery system that can carry therapeutics with various BCS classes of drugs. The extraordinary deformability and elasticity of transferosomes allow them to pass through skin barrier constraints that are 5 to 10 times smaller than the diameter of vesicles. Regardless of the size, molecular weight, polarity, or structure of the agents they are carrying, transferosomes are incredibly adaptable and effective[ 18 ]. In this research, an attempt has been made to prepare transferosome patches of both the drugs of different BCS classes, RTG (BCS class II) and RSM (BCS class III). RSM is a selective inhibitor of the enzyme MAO-B, which is responsible for the degradation of dopamine in the brain. On the other hand, RTG HCL is a dopamine agonist that ultimately raises the levels of dopamine in the brain. The RSM can attract and interact with water, and when it is in the form of transferosomes, it enables the drug to get through the blood-brain barrier. These transferosomes are very flexible vesicles that prevent the activeitransferasesB enzyme, resulting in a decrease in the breakdown of dopamine. Additionally, RTG HCL is responsible for increasing the concentration of dopamine. Ultimately, the therapy for Parkinson's disease will result in an elevated concentration of dopamine in the brain. Ultimately prepared formulation was evaluated with different parameters to check the effects of both drugs in the in vivo study. 2 Materials and method RTG was kindly gifted by Neuland Laboratory Mumbai, and RSM was procured from Benzchem Enterprise Vadodara. 2.1 Materials 2.2 Method of preparation of transferosome Patches Transferosome patches were prepared by suspension homogenize followed by the casting method. To brief, Transferosomes of both drugs were prepared with the thin film hydration method as reported by Patel Shivani et al.[ 25 ]. To prepare the polymeric solution of an appropriate quantity of ethylcellulose (EC), HPMC K4M, Eudragit RS 100, and Eudragit RL 100, Mix all the solid ingredients in a beaker and add 7.5 ml of methanol and 7.5 ml of isopropyl alcohol dropwise, stirring until a homogeneous solution is obtained. After getting the homogenous solution, add a transferosome solution equivalent to 1 mg of each drug to this solution, add 0.6 ml of dibutyl phthalate, and again allow for homogenous mixing. Cast this polymeric solution on a backing membrane and allow it to dry in a preheated hot air oven at 60°C for 2 hours by covering the petri dish with an inverted funnel. Store the patches at room temperature in a dry place. 2.3 Optimization of transdermal Patches After the literature survey and preliminary trials, patches were optimized by applying a central composite design. In optimization design, dependent variables are selected at three levels, and two variables are selected. The independent variables are the (A) amount of Eudragit R, (B) amount of Eudragit RL, and (C) amount of HPMC K4M, and the dependent variables are (X1) percent drug release and (X2) tensile strength. The study matrix of central composite design with coded terms and actual terms is given in Table 1 . Table 1 Matrix of central composite design with coded and actual values for optimization of transdermal patches Batch Concentration of Eudragit RS (mg) (A) Concentration of Eudragit RL (mg) (B) Concentration of HPMC K4M (mg) (C) Actual value Y1 Y2 Y3 1 -1.00 1.00 -1.00 100 50 200 2 1.00 1.00 1.00 75 32.96 150 3 0.00 0.00 0.00 75 75 150 4 1.68 0.00 0.00 75 75 150 5 0.00 0.00 0.00 117.04 75 150 6 1.00 -1.00 -1.00 75 75 150 7 -1.00 -1.00 -1.00 100 100 100 8 -1.00 -1.00 1.00 32.96 75 150 9 0.00 0.00 -1.68 50 100 100 10 0.00 0.00 1.68 50 100 200 11 1.00 -1.00 1.00 75 117.04 150 12 0.00 1.68 0.00 75 75 234.09 13 -1.00 1.00 1.00 50 50 200 14 0.00 -1.68 0.00 75 75 150 15 0.00 0.00 0.00 100 50 100 16 0.00 0.00 0.00 100 100 200 17 -1.68 0.00 0.00 50 50 100 18 0.00 0.00 0.00 75 75 150 19 1.00 1.00 -1.00 75 75 150 20 0.00 0.00 0.00 75 75 65.91 3 Evaluation of Transdermal Patches 3.1 Thickness The thickness of the patches is essential for their brittleness. Thickness is dependent on the area of the Petri plate to be spread. The thickness of the patches was measured using a screw gauge at six different points. Values were recorded, and the mean with standard deviation (center and corners), a screw gauge, and a mean value of five locations were used as a film thickness[ 26 ]. 3.2 Weight variation The weight variation assessment was done by weighing 10 patches that were randomly selected on a digital balance in triplicate for each patch. The average weights were calculated, and the standard deviation from the average weights was measured[ 27 ]. 3.3 Folding endurance The folding endurance is defined as the number of folds required to break any polymeric patch of RTG and RSM-loaded transferosomal transdermal patches. It was measured manually by folding the patch (2 × 2 cm) on the same site until it was broken. The number of counts required to break the patch on the same site is considered the folding endurance of the patch. Repeat this procedure three times for a single patch and record the value with means. Three patches of each type were taken for the test. 3.4 Tensile strength The tensile strength of each patch was measured using an in-house modified assembly, as shown in Fig. 1 . A patch of 2×2 cm was used for the study. One end of the patch was fixed to the surface, and the other end was attached to the thread to which weight was applied. (One end of the thread was fixed with a patch, and the other end of the thread is attached to the assembly, which holds the weight to be applied.) Record the weight at which the patch starts to break and calculate it with the given equation. $$\:\mathbf{T}\mathbf{e}\mathbf{n}\mathbf{s}\mathbf{i}\mathbf{l}\mathbf{e}\:\mathbf{s}\mathbf{t}\mathbf{r}\mathbf{e}\mathbf{n}\mathbf{g}\mathbf{t}\mathbf{h}=\:(\mathbf{b}\mathbf{r}\mathbf{e}\mathbf{a}\mathbf{k}\:\mathbf{f}\mathbf{o}\mathbf{r}\mathbf{c}\mathbf{e}/\mathbf{a}\:\times\:\:\mathbf{b})\:\times\:\:(1+\mathbf{L}/\mathbf{I})\:$$ Where a is width, b is thickness, L is length, and I is elongation 3.5 Drug content uniformity The drug content uniformity was performed to check the uniform distribution of RTG and RSM in transferosome-loaded patches. The amount of drugs contained in the patch was determined by dissolving Each patch of 2×2 cm was cut from different sections, weighed in methanol, kept for stirring by using a magnetic stirrer for 24 hours, and filtered. Appropriate dilutions were made with phosphate buffer, and the resulting solution was filtered through a Watman filter paper. Drug content was measured spectrophotometrically at a λmax at 239 nm and 273 nm respectively with a linear equation[ 28 ]. 3.6 Moisture content study Moisture content is important to check as it is directly applied to the skin membrane. The prepared patches were weighed and kept in a desiccator containing activated silica at room temperature for 24 hours. The individual films were weighed every alternate day until a constant weight was achieved. The percentage of moisture content was calculated by determining the difference between the initial and final weights for the final weight[ 28 ]. The moisture content was calculated by the following equation. 3.7 Elongation The percentage of elongation of the films was measured by fixing one end of the film between the two iron screens to support the film, and another was connected to the paper holder in which the hook was inserted. A thread was tied to this hook, passed over the pulley, and a small pan was attached to the other end to hold the weight. A small pointer was attached to the thread, which travels over the scale affixed to the base plate. The elongation was determined by recording the distance traveled by the pointer before the film's break on the scale[ 29 ]. The elongation was determined using the following formula: $$\:\varvec{\%}\:\varvec{E}=(L1-L2)/L2*100$$ where L1 is the final length of the patch, and L2 is the initial length of the patch. 3.8 In vitro drug release studies The in vitro drug release profile is utilized as a scientific tool to optimize the transferosomal formulation by providing fundamental information on formulation design and specifics on the release mechanism and kinetics. An in vitro drug release study was performed using the Franz diffusion apparatus with a phosphate buffer pH of 7.4. To perform the in vitro drug release of transdermal matrix-type patches, The MWCO of cellophane membranes typically falls in the range of approximately 6,000 to 14,000 Daltons. The transdermal film was set on top in the donor compartment and covered with aluminum foil, while the membrane was positioned between the donor and receptor compartments of a diffusion cell. The receptor compartment was heated to 37 ± 0.5°C, which is the average body temperature of an adult human, and allowed for continuous stirring with magnetic beads at 100 rpm speed on a hot plate magnetic stirrer. Samples were collected at various time intervals (0, 5, 10, 15, 20, and 25 hr.) and evaluated for drug content with UV-spectrophotometry. Following each sample withdrawal, an equal volume of phosphate buffer was added to the receptor phase[ 30 ]. 3.9 Ex vivo drug permeation studies The ex vivo permeation studies were conducted using Franz diffusion cells and Wistar rat skin. For these experiments, full-thickness abdominal skin (with approx. thickness: 0.5 mm to 1.5 mm) samples from Wistar rats weighing between 200 and 250 grams were employed. Before the initiation of the study, the abdominal hair in the designated region was gently removed using an electric clipper, and the dermal side of the skin specimens underwent thorough cleansing with distilled water to remove any adhering tissues or blood vessels. Subsequently, the skin samples were allowed to soak in a phosphate buffer solution with a pH of 7.4 for one hour. This step was essential to ensure that the skin reached an equilibrium state in terms of moisture content and pH before the commencement of the experiment. Once the skin preparation was completed, transdermal patches (1 cm x 1 cm) were applied to the skin surface. To promote the uniform distribution of the diffusion across the skin surface, a magnetic stirrer equipped with a small magnetic bar was utilized. Throughout the experiment, precise temperature control was maintained within the Franz diffusion cell at 37 ± 0.5°C, achieved through the use of a thermostatically regulated heater. At predefined time intervals, 5 ml of sample was withdrawn. To maintain a sink condition, fresh phosphate buffer with a pH of 7.4 was added. The samples were subsequently filtered using the Whatman filter paper and subjected to analysis through a developed and validated simultaneous first-order derivative method employing a UV-spectrophotometer[ 31 ]. The percentage of drug permeated was calculated based on these analyses. 3.10 In vivo skin irritancy studies Animal experimentation serves as a pivotal component in the assessment of formulation efficacy and potential toxicity. In this context, an animal study was conducted to compare the effects and irritancy of two distinct formulations. The experimental protocol received ethical approval from the Institutional Animal Ethical Committee at Parul Institute of Pharmacy and Research, India, bearing reference no. PIPR 984/2022/02. Following the guidelines established by the Organisation for Economic Co-operation and Development (OECD), specifically OECD 404, the dermal toxicokinetic study necessitated the selection of animals of either sex aged between 6 and 12 weeks, and groups made as shown in Table 4 . Before testing, the dorsal area of the trunk of the test animals was carefully clipped. Shaving was performed approximately 24 hours before initiation of the study, with meticulous attention to prevent any skin abrasion that could potentially influence skin permeability[ 32 ]. Approximately 10% of the body surface area was cleared to ensure optimal application of the test substance. Subsequently, all animals underwent a comprehensive examination for the presence of erythema and edema. These responses were meticulously assessed and documented at several time points, including 60 minutes 24, 48, and 72 hours following the removal of the test patches. Additionally, an immediate post-patch removal examination was conducted in one animal, with subsequent grading and documentation of dermal reactions. 3.11 Pharmacokinetic studies Pharmacokinetic studies assume paramount importance in early-stage drug development due to their capacity to unravel the Absorption, Distribution, Metabolism, and Excretion (ADME) properties of pharmaceutical compounds. These investigations yield critical insights into various aspects, including the potential impact of food interactions, drug-drug interactions, and organ impairment on drug disposition. Pharmacokinetics constitutes a pivotal domain of scientific inquiry, offering invaluable data regarding the intricate behavior of molecules within biological organisms. The experimental protocol underwent rigorous scrutiny and attained ethical approval from the Institutional Animal Ethical Committee at Parul Institute of Pharmacy and Research, India, bearing the reference number PIPR 984/2022/02/17.In strict conformance with the guidelines stipulated by the Organization for Economic Co-operation and Development (OECD) 417, the dermal toxicokinetic study necessitated the selection of twelve animals, disregarding gender, aged within the range of 6 to 12 weeks. In the preparatory phase, meticulous fur clipping from the dorsal trunk area of the test animals occurred immediately before the onset of the study. Shaving procedures were executed approximately 24 hours before the study initiation, with utmost care taken to prevent any potential skin abrasions that could influence skin permeability. Approximately 10% of the body surface area was intentionally cleared to ensure precise application of the transdermal patch containing the test substance. Following patch application, blood samples were systematically collected at predefined intervals, specifically at 0, 1, 2, 3, 4, 6, 12, 18, and 24 hours post-application. The isolation of plasma from the collected blood samples involved centrifugation at 10,000 revolutions per minute for 15 minutes, with temperature control maintained at 20°C. Subsequently, quantification of plasma concentrations was performed using a meticulously developed and rigorously validated High-Performance Liquid Chromatography (HPLC) bioanalytical method (unpublished work). Pharmacokinetic parameters were then derived based on the acquired datasets of stability Studies The stability assessment of the formulation was conducted under two distinct environmental conditions. Various parameters including the percentage of in vitro drug release, percentage of drug content, tensile strength, and Fourier-transform infrared (FTIR) spectroscopy analysis were meticulously evaluated at designated time points encompassing days 0, 30, 60, and 90[ 33 ]. 4 Results and Discussion 4.1 Statistical analysis All the statistical calculation was performed using a DOE. Data are expressed as mean ± S.D. Data were analyzed statistically using analysis of variance (ANOVA). A p-value less than 0.05 was considered statistically significant[ 34 ]. Optimization of transferosomal patches was performed using a Central Composite Design. A total of 20 batches were suggested by the Design of Experiments software. These batches underwent evaluations for several parameters, including thickness uniformity, folding endurance, drug content uniformity, tensile strength, and ex-vivo drug diffusion. The acquired responses were then analyzed using Design Expert software and fitted into various polynomial models, such as linear, two-factor interaction (2FI), cubic, and quadratic models. A quadratic model was proposed for both the in-vitro drug release (Y1) and tensile strength (Y2) responses. The F16 batch was selected as the optimized batch because it demonstrated good in-vitro drug release and tensile strength, as shown in Table 2 . As the concentrations of the selected independent variables increased, there was a decrease in in-vitro drug release. The greater density produced a more compact matrix, which restricted the movement and diffusion of the drug molecules, thereby slowing down the drug release. Conversely, as the concentration of independent variables increased, there was an increase in tensile strength. HPMCK4M and Eudragit contributed to the mechanical strength and flexibility of the formulation, thus potentially improving its folding endurance. However, during studies, it was observed that at optimum concentration results are better. The F16 batch shows 93.79% In-Vitro drug release of RTG and 91.82% of RSM. Which is the maximum %CDR amongst all batches. The Tensile strength demonstrated 0.1257035 kg/cm2. The responses showed the opposite effect beyond optimized concentration. Hence F16 batch was selected as it showed better results than other batches. Beyond optimized concentrations, In vitro drug release started to decrease. Table 2 Measures and Responses of Optimization of Transferosomal Patch Batch A (Amt of eudragit RS 100) B (Amt of eudragit RL 100) C (Amt of HPMCK4M) Y1 Y2 Y2 1 50 50 100 74.74 72.47 0.067208 2 100 50 100 67.79 65.52 0.062842 3 50 100 100 63.34 58.82 0.061837 4 100 100 100 66.76 62.68 0.145369 5 50 50 200 87.69 80.75 0.096352 6 100 50 200 61.68 58.26 0.097145 7 50 100 200 71.34 67.62 0.186718 8 100 100 200 72.73 68.5 0.284874 9 32.9 75 150 76.84 73.82 0.083913 10 117.04 75 150 66.78 64.04 0.224036 11 75 32.9 150 75.14 71.61 0.085506 12 75 117.04 150 62.99 60.87 0.229321 13 75 75 65.9 68.31 63.49 0.025274 14 75 75 234 73.74 71.23 0.183092 15 75 75 150 93.76 91.54 0.125506 16 75 75 150 93.79 91.82 0.125703 17 75 75 150 93.03 91.14 0.125818 18 75 75 150 93.30 91.69 0.125884 19 75 75 150 93.06 91.47 0.125101 20 75 75 150 93.7 91.39 0.1252 4.1.1 Statistical interpretation of Tensile strength The R-squared value for tensile strength is 0.9745, as shown by the summary statistics for tensile strength provided by the Design Expert software. The main effects are statistically significant, according to the quadratic model. The terms A, B, and C are considered to be the main effects because the value of "Prob > F" is less than 0.0500. On the other side, values higher than 0.1000 imply that the model terms are not important. The F-value for the model, which is 42.503, indicates that the model is significant. The p-value of AB is less than 0.05 which indicates interaction of eudragit RS 100 and eudragit RL 100 is significant same way p-value for BC is also less than 0.05 which indicates that eudragit RL 100 and HPMCK4M shows a significant interaction. The polynomial equation suggests the negative effect of A and B and the positive effect of C term on tensile strength. Final Equation in Terms of Coded Factors : Full Polynomial Equation Tensile strength = + 91.52–3.01 * A -2.74 * B + 2.10 * C + 4.27* A * B -+1.70 * B * C -8.39 * C 2 Reduce Polynomial Equation Tensile strength = -3.01 * A -2.74 * B + 2.10 * C 4.1.2 Statistical interpretation of RTG in vitro release The R-Squared In Vitro drug release is 0.9805, as shown by the summary statistics for In-Vitro drug release provided by the Design Expert software. The main effects are statistically significant, according to the quadratic model. The terms A, B, and C are considered to be the main effects because the value of "Prob > F" is less than 0.0500. On the other side, values higher than 0.1000 imply that the model terms are not important. The F-value for the model, which is 55.909304, indicates that the model is significant (Table 4.25). The p value of AB is less than 0.05 which indicates interaction of eudragit RS 100 and eudragit RL 100 is significant same way the value for AC is also less than 0.05 which indicates that eudragit RS 100 and HPMCK4M shows significant interaction. The polynomial equation suggests the negative effect of A and B and the positive effect of C term on in vitro drug release. Final Equation in Terms of Coded Factors for RTG : Full Polynomial equation % In-Vitro drug release = + 93.49–3.30 * A -2.79 * B + 2.19 * C + 4.72 * A * B -2.64 * A * C -7.36 * A 2 -8.33 * B 2 -7.64 * C 2 Reduce polynomial equation % In-Vitro drug release = + 93.49–3.30 * A -2.79 * B + 2.19 * C 4.1.3 Statistical interpretation of in vitro release The R-squared value for the Response Surface Methodology In Vitro drug release is 0.9919, as indicated by the summary statistics provided by the Design Expert software. The quadratic model shows that the main effects are statistically significant. The terms A, B, and C are considered the main effects because the "Prob > F" values are less than 0.0500. On the other hand, values greater than 0.1000 suggest that the model terms are not important. The model's F-value of 136.54 indicates that the model is significant. The p-value, which is less than 0.05, suggests a significant interaction between Eudragit RS 100 and Eudragit RL 100. Similarly, the p-value for the interaction between Eudragit RS 100 and HPMC K4M is also less than 0.05, indicating a significant interaction. The polynomial equation suggests a negative effect of factors A and B and a positive effect of factor C on in-vitro drug release. Final Equation in Terms of Coded Factors for RSM Full Polynomial Equation % In-Vitro drug release = + 91.52–3.01 * A -2.74 * B + 2.10 * C + 4.27 * A * B -2.31 * A * C + 1.70 * B * C -7.83 * A 2 -8.78 * B 2 -8.39 * C 2 Reduce polynomial Equation % In Vitro drug release = + 91.52–3.01 * A -2.74 * B + 2.10 * C The overlay plot for the formulation was obtained from design expert 7. In the overlay plot, the yellow region indicates the area in which optimized formulation can be formulated. Hence the yellow portion indicates values of A, B & C which were near to the values of formulation F16. The values of responses in vitro drug release and Tensile strength of formulation F16 which is desirable and good compared to other batches. Therefore, the formulation F16 was taken as an optimized batch of RTG & RSM transdermal patch. Table 3 Results for validation batches Response Predicted results Observed results Mean ± SD % In vitro Drug Release RTG 94.1277% 94.01 ± 0.002% % In vitro Drug Release RSM 92.0207% 92.23 ± 0.0103% Tensile strength 0.130189 kg/cm2 0.13143 kg/cm2 4.2 Results of Optimization of Transdermal Patches 4.2.1 Thickness the observed augmentation in patch thickness with increasing HPMCK4M content is a consequence of the enhanced availability of polymeric chains and the subsequent formation of a denser polymeric network within the patch matrix. This phenomenon underscores the pivotal role of HPMCK4M in influencing the physical attributes and characteristics of the transdermal patches. Weight variation For the weight variation patches were randomly selected and weighed on analytical balance thrice. Recorded values were then calculated for mean and standard deviation values. 4.2.2 Folding endurance The folding endurance of the patches was found to be 111 and 109 respectively for both drugs. In essence, HPMCK4M and Eudragit polymers play a pivotal role in bolstering the mechanical properties of the patch, ultimately contributing to its remarkable folding endurance. This, in turn, underscores their significance in ensuring the patch's functionality and integrity under diverse mechanical stresses. 4.2.3 Tensile Strength The acquired data revealed that the recorded tensile strength values for the two distinct patches under investigation were as follows: 0.13143 kg/cm² and 0.1389 kg/cm², respectively. These values represent the force per unit area required to cause the patch to fracture or rupture when subjected to tensile forces. Higher tensile strength values signify increased resistance to stretching or pulling, which can be advantageous for ensuring the structural integrity and durability of the patch in various practical applications. The obtained results demonstrate the positive effect of independent variables on the response, namely the tensile strength of the patch. As the concentrations of HPMCK4M, Eudragit RS100, and Eudragit RL100 increase, the tensile strength also increases. This is due to the ability of HPMCK4M, Eudragit RS100, and Eudragit RL100 to modify the characteristics of the patch's polymer matrix. They enhance the matrix's cohesiveness and flexibility, thereby bolstering its mechanical strength. Consequently, the patch's tensile strength experiences an enhancement. It is well-established that HPMCK4M, Eudragit RS100, and Eudragit RL100 can reinforce polymeric matrices. When incorporated into a patch, they can function as fillers or reinforcers within the polymer matrix. The greater tensile strength results from the patch's heightened resistance to deformation and breakage, attributed to the presence of these reinforcing agents. 4.2.4 Drug content uniformity The drug content in different transdermal preparations containing RTG ranged from 98.3-102.1% and for RSM 97.7 to 101.6%. Notably, the transdermal film formulation labelabeledF16 demonstrated nearly 99.4% drug content of RSM and 101.9% drug content of RSM. The distribution of the drug within the transdermal films was uniform, and minimal drug loss occurred during or after the formulation process. 4.2.5 Moisture content study The moisture content within the transdermal films was found to exhibit a range between 0.36% and 5.8%. Notably, an observable trend emerged with the increment of HPMC concentration, as it directly corresponded to an increase in the percentage of moisture content within the films. This phenomenon underscores the influence of HPMC concentration on the films' moisture-absorbing capacity. 4.2.6 Elongation The elongation properties of the two investigated patches were quantified and found to be 29 and 31, respectively. Notably, one of the components employed in the formulation, Hydroxypropyl Methylcellulose (HPMC), is a hydrophilic polymer frequently employed in pharmaceutical applications as a film-forming agent. HPMC imparts enhanced elasticity and flexibility to the formulation. Generally, the elongation characteristics of the material can be augmented by elevating the concentration of HPMC. This effect is attributed to HPMC's capability to generate a pliable film that can undergo stretching before experiencing fracture. In contrast, certain copolymers such as Eudragit RL and RS, which exhibit a greater hydrophobic propensity compared to HPMC, are commonly utilized in applications like enteric coatings or controlled-release systems. These Eudragit polymers, relative to HPMC, often demonstrate reduced elongation properties. They produce films characterized by diminished stretchability and increased stiffness. 4.2.7 In vitro drug release of RSM and RTG The results for the release of RTG are within the range of 61.68 ± 0.941 to 93 ± 0.479, while for RSM, it falls within the range of 58.26 ± 0.317 to 91.82 ± 0.293. Batch 16 is considered the optimized batch, as it exhibits a significant drug release for both RTG and RSM. Based on the in vitro release results of RTG and RSM, it can be inferred that an increase in the number of polymers leads to a decrease in the release of both drugs over a 24-h24 hours phenomenon is attributed to the presence of polymers such as HPMC, Eudragit RS, and Eudragit RL 100, which are commonly used in drug patches to regulate drug release. As the concentrations of these polymers increase, the overall polymer density in the patch also rises, resulting in a more compact matrix. This denser matrix restricts the movement and diffusion of drug molecules, thereby slowing down drug release. Another contributing factor to the decreased drug release in patches with higher polymer concentrations is the development of a thicker surface layer or barrier. At higher polymer concentrations, this physical barrier layer acts as an impediment, preventing the drug from diffusing out of the patch. The increased thickness of this layer further limits drug release, resulting in a slower release rate. HPMC, Eudragit RS 100, and Eudragit RL 100 can interact with drug molecules through various processes, such as hydrogen bonding or hydrophobic contact. Higher polymer concentrations increase the number of polymer chains available to interact with the drug. These interactions can result in stronger binding or association between the polymer and drug molecules, further contributing to the slowing of drug release. Figures 5 and 6 provide graphical representations of the in vitro drug release results. 4.2.8 Ex vivo drug permeation studies The transdermal film formulation F16 demonstrated drug permeation rates of 92.73 ± 0.054% for RTG and 84.87 ± 0.002% for RSM within a 24-hour timeframe, as illustrated in Figs. 8 and 9 . The plotted graphs (% CDR vs. time) for the optimized batch indicated coefficient of determination (R²) values of 0.9036 for RTG and 0.9445 for RSM, respectively, over the 24-hour duration. These results affirm that the transdermal formulation effectively releases the drug at an appropriate skin flux throughout the entire 24-hour period in which maximum drug release was found in RTG formulation which is more than 92%. Furthermore, the graphical representation of the cumulative drug concentration (%) permeating through the rat's abdominal skin over time suggested that the drug permeation follows zero-order kinetics. Additionally, the formulation exhibited significant release kinetics following the Higuchi model, with R² values of 0.959 for RTG and 0.9372 for RSM. These findings underscore the formulation's adherence to the Higuchi model, indicating a controlled and consistent release pattern. 4.2.9 Skin Irritancy studies To comprehensively evaluate the potential effects of continuous transdermal patch usage on the skin, a skin irritancy test was meticulously conducted. The Draize method, a well-established approach for assessing skin irritation, was employed, utilizing a skin irritation index to systematically inspect and grade the results. The transdermal patch was applied to the skin of the experimental subjects for a few hours. During this period, a thorough examination of the rat's skin was conducted to detect any indicators of erythema (skin redness) or edema (swelling). Notably, the observations made during this initial 48-hour period, as depicted in Fig. 10 and Table 4 , revealed the absence of any erythematous or edematous symptoms. Building on these findings, the study was extended to a 72-hour timeframe. Remarkably, even after this prolonged duration of patch application, there remained no observable erythema or edematous symptoms on the skin. These consistently favorable results strongly suggest that the long-term usage of the transdermal patch containing RSM and RTG poses no discernible skin irritancy risks. In essence, the systematic assessment conducted through the Draize method, coupled with the extended observation period, provides robust evidence supporting the safety of prolonged and continuous usage of the RSM and RTG transdermal patch, with no indications of skin irritation. Table 4 Observation of Skin Irritancy Studies Groups No of animal Group 1: Normal control 2 Group 2: Treated with formulation 4 Evaluation parameter Observation Score Time 1 2 3 4 5 6 Erythema Oedema Hour 0 0 0 0 0 0 No erythema No oedema 0 3 (min) 0 - - - - - Very slight erythema (barely perceptible) Very slight edema barely perceptible) 1 1 0 - - - - - 4 0 0 0 0 0 0 Well defined erythema Slight oedema 2 12 0 0 0 0 0 0 Moderate to severe erythema Moderate oedema 3 48 0 0 0 0 0 0 Severe erythema Severe oedema 4 72 0 0 0 0 0 0 4.2.10 In vivo pharmacokinetic studies The application of the transferosomal patch was subjected to comprehensive pharmacokinetic analysis, comparing it with both a single dose of RSM nanoparticles following intravenous (i.v.) administration and Neupro. This evaluation was based on the analysis of plasma drug concentration-time profiles, as detailed in the pharmacokinetic parameters presented in Table 5 . Upon patch administration, the initial plasma concentration values within the first 2–3 hours fell below the lower limit of quantification defined by the analytical method. In contrast, the intravenous formulation of RSM exhibited a significantly faster initial drug release rate, reaching its peak plasma concentration promptly. Specifically, quantifiable plasma concentrations were achieved at 3 hours for RSM and 2 hours for RTG. The maximum observed plasma concentration (Cmax) was 199.3 ng/ml for RSM and 107.6 ng/ml for RTG. Furthermore, the time required to attain maximum plasma concentration was notably prolonged, taking 12 hours for RSM and 18 hours for RTG. The elimination half-life (t½) values for RSM and RTG were observed to be 18 hours and 33 hours, respectively. These values, when compared with standard reference data provided in Table 5 , indicate that both drugs exhibit extended half-lives when administered in the form of a transferosomal patch. Furthermore, a noteworthy increase in the area under the concentration-time curve (AUC), a critical pharmacokinetic parameter, was observed for both drugs. Specifically, the AUC of RSM increased six-fold, while that of RTG increased twelve-fold, signifying a substantial enhancement in the bioavailability of both drugs following transferosomal patch application. Regarding sustained drug release, RSM concentrations remained above the limit of quantification (LOQ) for 24 hours, while RTG concentrations persisted above LOQ for 36 hours. After these respective time points, drug concentrations in plasma fell below the limit of detection (LOD). This observation indicates that the formulated patches have RSM for up to 24 hours and RTG for up to 36 hours with significant quantities. In summation, the comparative analysis of the obtained data against reference data suggests that the transferosomal patch not only substantially enhances the bioavailability of both drugs but also achieves controlled and sustained drug release into plasma over a 24-hour duration. Table 5 Comparison of actual pharmacokinetic parameters with reported values Pharmacokinetic Parameters Reported (RM -NPs IV) Actual Reported (Neupro) Actual C max (ng. ml) 97 .34 ± 5.10 199.3 ± 6.01 9.83 ± 2.80 107.6 ± 1.17 T max (h) 0.5 ± 0.02 12 ± 0.019 7.33 ± 2.4 18 ± 3.24 T 1/2 (h) 2.68 ± 0.95 18.1350 ± 3.13 22.35 ± 12.83 33.44 ± 1.10 AUC(mg ⋅ h/ml) 388.41 ± 19.75 2403.24 ± 7.11 169.39 ± 30.77 2253.655 ± 2.15 MRT(h) 3.94 ± 0.83 7.5 ± 1.51 - 10.09 ± 4.02 4.2.11 Stability Study of Formulation Stability studies of the formulation were conducted under distinct environmental conditions to rigorously evaluate its robustness. Parameters including % in vitro drug release, % drug content, tensile strength, and FTIR were systematically assessed at predefined intervals, specifically at days 0, 30, 60, and 90. The outcome of the stability studies unequivocally affirms the physical and chemical stability of the formulation. Comprehensive results, as depicted in Table 6 and illustrated in Fig. 11 and Fig. 12 , provide a detailed overview of the formulation's stability performance over the designated time points. Table 6 Results of stability studies Time Specifications % In-Vitro drug release % Drug Content Tensile strength RTG RSM RTG RSM Day 0 RT 93 ± 0.6 91.82 ± 0.29 98.3 ± 0.001 99.06 ± 0.007 124.81 ± 0.005 40 ± 2°C, 75 ± 5% RH 93.24 ± 0.6 91.21 ± 0.2 98.02 ± 0.001 99 ± 0.0073 124.75 ± 0.005 Day 30 RT 93.1 ± 0.74 90.77 ± 0.1 97.81 ± 0.001 98.69 ± 0.004 125.08 ± 0.0024 40 ± 2°C, 75 ± 5% RH 93.41 ± 0.7 90.83 ± 0.1 97.52 ± 0.001 98.77 ± 0.004 125.13 ± 0.0024 Day 60 RT 92.7 ± 0.19 90.52 ± 0.1 98.01 ± 0.001 98.9 ± 0.0013 125.11 ± 0.00181 40 ± 2°C, 75 ± 5% RH 92.81 ± 0.1 90.85 ± 0.1 98.05 ± 0.001 98.6 ± 0.0013 124.51 ± 0.00181 Day 90 RT 92.1 ± 0.75 90.68 ± 0.2 98.03 ± 0.004 98.57 ± 0.002 125.45 ± 0.0061 40 ± 2°C, 75 ± 5% RH 92.01 ± 0.7 90.79 ± 0.2 98.01 ± 0.004 98.83 ± 0.002 125.05 ± 0.0061 5 Conclusion In this study, we set out to address the pressing need for improved treatment options for Parkinson's disease, given the significant and projected increase in cases by 2040. The main goal of our study was to create transferosome patches that held two drugs from two different Biopharmaceutics Classification System (BCS) classes: RTG (BCS class II) and RSM (BCS class III). These patches were rigorously evaluated using a comprehensive set of parameters. The results obtained from this investigation are promising. The transferosomal patches exhibited favorable characteristics, including good tensile strength and controlled drug release, which are essential for an effective drug delivery system. Moreover, the pharmacokinetic studies revealed a rapid onset of action, which is particularly valuable for a condition like PD, where quick relief can significantly improve the patient's quality of life. Additionally, the in vivo skin irritancy studies indicated that the application of these patches did not cause any damage to the local tissue, demonstrating their safety. While the results of this study indicate the potential of the prepared transferosomal patches in Parkinson's disease treatment, it is important to acknowledge the typographical error in the abstract's conclusion. The study has shown potential for Parkinson's disease treatment rather than Alzheimer's. The research on transferosome patches for Parkinson's disease holds significant promise for advancing drug delivery in this field and addressing neurodegenerative disorders. The success of these patches in the study encourages further investigations and improvements. This includes the imperative transition from preclinical evaluations to rigorous clinical trials, shedding light on the effectiveness and safety of transferosome patches in human patients. Continuous optimization of patch formulations can lead to even more effective drug delivery systems, with potential refinements in drug release profiles and therapeutic outcomes. Exploring combination therapies by incorporating other therapeutic agents alongside RTG and RSM within the transferosome patches offers the potential for more comprehensive treatment strategies. Additionally, assessing the long-term efficacy and durability of these patches is essential to confirming their sustained benefits in managing Parkinson's disease symptoms. Personalized medicine approaches, involving the customization of patch compositions to individual patient profiles, could lead to more targeted and effective therapies. Comparative studies against existing treatments, including medications and surgical interventions, will help provide a comprehensive assessment of the advantages and limitations of the transferosome patch approach. This research sets the stage for a dynamic and transformative future in Parkinson's disease treatment and drug delivery. In conclusion, this research paves the way for the development of innovative and patient-centric treatment options for Parkinson's disease. The successful formulation and evaluation of transferosome patches offer a promising avenue for future research and clinical translation, potentially revolutionizing the management of this debilitating condition. Declarations Acknowledgment The authors are thankful to Neuland Laboratory Limited, Mumbai, India for providing Retigabine HCl as a gift sample. The authors are also thankful to Dr. Guno Chakraborty and Dr. Snigdha Mandal Das for guiding in animal studies. Additionally, the authors are thankful to the management of Parul University for providing the infrastructure requirement for the research. Ethics approval and consent to participate Ethics approval was done by the Institutional Animal Ethical Committee at Parul Institute of Pharmacy and Research, India, bearing reference no. PIPR 984/2022/02/17. Consent for publication Not Applicable Availability of data and materials Not Applicable Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Authors' contributions Sr. No. Name of Author Role(s) of Author 01 Shivani Patel Concept, Data compilation, Interpretation, Writing - Original Draft 02 Lalit Lata Jha Supervision, Writing - Review & Editing 03 Riya Patel Writing & Editing References Torpy JM, Lynm C, Glass RM. Parkinson Disease [Internet]. JAMA. 2004 [cited 2023 Oct 12]. p. 390. Available from: https://www.who.int/news-room/fact-sheets/detail/parkinson-disease Bloem BR, Okun MS, Klein C. Parkinson’s disease. The Lancet. 2021;397:2284–303. De Caro V, Giandalia G, Siragusa MG, Sutera FM, Giannola LI. New prospective in treatment of Parkinson’s disease: Studies on permeation of ropinirole through buccal mucosa. Int J Pharm. 2012;429:78–83. Of D, Accurate AN, Spectroscopic U V, For M, In T, Buffers V. SHORT COMMUNICATIONS DEVELOPMENT OF AN ACCURATE UV SPECTROSCOPIC METHOD FOR TINIDAZOLE IN VAGINAL BUFFERS. 2024;61:64–7. Aung TY, Soo S. Drugs Induced Nausea and Vomiting: an Overview. IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS. 11:5–09. Elshoff JP, Cawello W, Andreas JO, Mathy FX, Braun M. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson’s disease and restless legs syndrome. Drugs. 2015;75:487–501. Lecht S, Haroutiunian S, Hoffman A, Lazarovici P. Therapeutics and Clinical Risk Management ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/dtcr20 Rasagiline-a novel MAO B inhibitor in Parkinson’s disease therapy. 2007; Shehab-ElDin AN, Sobh RA, Rabie AM, Mohamed WS, Nasr HE. Polyamide 6/tallow modified clay nanofibrous mat coupled with hydrogels for potential topical/transdermal delivery of doxycycline hydrochloride. J Pharm Investig. 2023;53:307–21. Patel G, Patel P, Sonara Z, Patel R, Pharm ( M. Fabrication and Optimization of 3D Printed Insert Coated With Rate Controlling Membrane in the Treatment of Recurrent Vaginal Candidiasis Via Vaginal Route. [cited 2023 Aug 24]; Available from: https://ssrn.com/abstract=4514316 Patel R, Shah U, Patel G. Optimization of poly(Ε-caprolactone) based biodegradable in situ porous drug-eluting insert of BCS class II/IV drug for targeted application. International Journal of Polymeric Materials and Polymeric Biomaterials [Internet]. 2024 [cited 2023 Jul 18];73:885–96. Available from: https://www.tandfonline.com/doi/abs/10.1080/00914037.2023.2222334 shah S, Patel R, Patel G. Nanocomposite hydrogels: an optimistic insight towards the treatments of ocular disorders. Recent Pat Nanotechnol [Internet]. 2023 [cited 2023 Aug 24];17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/37519202 Shah S, Patel AA, Prajapati BG, Alexander A, Pandya V, Trivedi N, et al. Multifaceted nanolipidic carriers: a modish stratagem accentuating nose-to-brain drug delivery [Internet]. Journal of Nanoparticle Research. Springer; 2023 [cited 2023 Aug 24]. p. 1–34. Available from: https://link.springer.com/article/10.1007/s11051-023-05804-4 Patel R, Yadav BK, Patel G. Progresses in Nano-Enabled Platforms for the Treatment of Vaginal Disorders. Recent Pat Nanotechnol [Internet]. 2022 [cited 2023 May 18];17:208–27. Available from: https://pubmed.ncbi.nlm.nih.gov/35762539/ Patel R, Patel G. Preparation and Characterization of a Novel Optimum Modified Liquisolid Compact to Enhance the Dissolution Profile of Mifepristone. Dissolut Technol. 2023;30:238–44. Patel R, Patel S, Momin I, Shah S. The Evolving Landscape of Colonoscopy: Recent Developments and Complication Management. Colonoscopy - Diagnostic and Therapeutic Advances [Internet]. 2024 [cited 2024 Mar 28]; Available from: undefined/chapters/1160312 Trivedi S, Shah S, Patel R. Review on novel oral iron formulations with enhanced bioavailability for the treatment of iron deficiency. J Drug Deliv Sci Technol. 2023;90:105181. Song JG, Lee SH, Han HK. Organic clay-based fast dissolving microneedles for efficient transdermal delivery of therapeutic proteins. J Pharm Investig. 2024;1–12. Opatha SAT, Titapiwatanakun V, Chutoprapat R. Transfersomes: A promising nanoencapsulation technique for transdermal drug delivery. Pharmaceutics. 2020;12:1–23. Patel R, Yadav BK, Patel G. Progresses in Nano-Enabled Platforms for the Treatment of Vaginal Disorders. Recent Pat Nanotechnol. 2022;17:208–27. Shah S, Patel AA, Prajapati BG, Alexander A, Pandya V, Trivedi N, et al. Multifaceted nanolipidic carriers: a modish stratagem accentuating nose-to-brain drug delivery. Journal of Nanoparticle Research. Springer; 2023. p. 1–34. Patel RJ, Pandey P, Patel AA, Prajapati BG, Alexander A, Pandya V, et al. Ordered mesoporous silica nanocarriers: An innovative paradigm and a promising therapeutic efficient carrier for delivery of drugs. J Drug Deliv Sci Technol. Elsevier; 2023. p. 104306. shah S, Patel R, Patel G. Nanocomposite hydrogels: an optimistic insight towards the treatments of ocular disorders. Recent Pat Nanotechnol. 2023;17. Sahu BP, Baishya R, Hatiboruah JL, Laloo D, Biswas N. A comprehensive review on different approaches for tumor targeting using nanocarriers and recent developments with special focus on multifunctional approaches. Journal of Pharmaceutical Investigation 2022 52:5. 2022;52:539–85. Elmowafy M, Al-Sanea MM. Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies. Saudi Pharmaceutical Journal. 2021;29:999–1012. Patel S, Jha LL. Application of Plackett-Burman and Box-Behnken Designs for Screening and Optimization of Rotigotine Hcl and Rasagiline Mesylate Transfersomes: a Statistical Approach. International Journal of Applied Pharmaceutics. 2023;15:238–45. Eckertová L. Thin Film Thickness and Deposition Rate Measurement Methods. Physics of Thin Films. 1977;52–71. Solutions POF, Of D, Valid M. Stage 6 Harmonization Official. 2012;08:1–5. Varia U, Joshi D, Jadeja M, Katariya H, Detholia K, Soni V. Development and evaluation of ultradeformable vesicles loaded transdermal film of boswellic acid. Futur J Pharm Sci [Internet]. 2022 [cited 2023 Aug 24];8:1–16. Available from: https://fjps.springeropen.com/articles/10.1186/s43094-022-00428-2 Kathpalia H, Patil A. Formulation and evaluation of orally disintegrating films of levocetirizine dihydrochloride. Indian J Pharm Sci. 2017;79:204–11. Speer I, Preis M, Breitkreutz J. Dissolution testing of oral film preparations: Experimental comparison of compendial and non-compendial methods. Int J Pharm. 2019;561:124–34. Patel SM, Jha LL. Simultaneous Uv Method Development for Determination of Rotigotine Hydrochloride and Rasagiline Mesylate. Indian Drugs. 2023;60:73–9. Hwang SJ, Lee JH, Choi JH, Oh GS, So HS, Park JB, et al. Development of a self-microemulsifying drug delivery system using a Dunnione to enhance bioavailability. J Pharm Investig. 2024;1–11. Patel R, Shah R, Patel A, Hadiya K, Parmar J, Patel G. Off-Label use of Raloxifene hydrochloride in uterine fibroids: A novel insert-based formulation approach and IN-VIVO preclinical evaluation. J Drug Deliv Sci Technol. 2023;84:104552. Hinkelmann K. Design and Analysis of Experiments. Design and Analysis of Experiments. 2012;3:1–566. Supplementary Files Graphicalab.jpg Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4761605","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":342831472,"identity":"0495ba67-9d23-43ea-a090-08cc23fcc67e","order_by":0,"name":"Shivani Patel","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA/0lEQVRIiWNgGAWjYPACCwYDZhBtYAMkGBsPENRwgEECpiUNpKWBSC0Q5mGoAB5gPiP34OcPFRL25uw8hp8LCs7brW0/DLSlxiYalxaZM+eSJQ6ckUjc2cxjLD3D4HbytjOJQC3H0nIbcGiRYO8xkDjYJpFgcJgtQZoHqMXsAFALY8Nh3FqYeYx/HPwnYQ/Ukvybx+Bcstn5hwS0sPeYSRxskGDccJj5GNCWA3ZmNwjZwnMuzeLMMYlEkBZrHoPkBLMbQFsS8PlFIvfwjYoaG3uD8webb/P8sbM3O5/+8MGHGhucWhgYeFC5iWCVCTiVY9Fij1fxKBgFo2AUjEgAAJRhXvXtljNsAAAAAElFTkSuQmCC","orcid":"https://orcid.org/0000-0001-8055-6022","institution":"LJ Institute of Pharmacy","correspondingAuthor":true,"prefix":"","firstName":"Shivani","middleName":"","lastName":"Patel","suffix":""},{"id":342831473,"identity":"7fc529fe-cb4e-4ecd-9f1a-39044ce0b960","order_by":1,"name":"Lalit Lata Jha","email":"","orcid":"","institution":"Parul University","correspondingAuthor":false,"prefix":"","firstName":"Lalit","middleName":"Lata","lastName":"Jha","suffix":""},{"id":342831474,"identity":"b4b8d782-2047-4b0d-a131-bd4de551ad19","order_by":2,"name":"Riya Patel","email":"","orcid":"","institution":"Indrashil University","correspondingAuthor":false,"prefix":"","firstName":"Riya","middleName":"","lastName":"Patel","suffix":""}],"badges":[],"createdAt":"2024-07-18 09:52:37","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4761605/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4761605/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":66649526,"identity":"52d96e21-e88c-40da-b22c-2afbaa9c02c1","added_by":"auto","created_at":"2024-10-15 07:28:24","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":468768,"visible":true,"origin":"","legend":"\u003cp\u003eIn-house assembly for measurement of tensile strength\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-4761605/v1/c96391b9619d102c759df618.png"},{"id":66649527,"identity":"74382089-3378-4fea-8e61-7c6e9d65ef67","added_by":"auto","created_at":"2024-10-15 07:28:24","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":747263,"visible":true,"origin":"","legend":"\u003cp\u003eContour plot \u0026amp; 3D surface plot of tensile strength of patches\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-4761605/v1/9eb79bc2ac1cff5eadb6690e.png"},{"id":66649528,"identity":"df9d828d-97c4-4a01-838e-f7da208c80b4","added_by":"auto","created_at":"2024-10-15 07:28:24","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":476549,"visible":true,"origin":"","legend":"\u003cp\u003eContour plot \u0026amp; 3D surface plot of RTG \u003cem\u003eIn vitro\u003c/em\u003e permeation\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-4761605/v1/a9979e3f646a9d9a1854a0c5.png"},{"id":66650552,"identity":"6c063f60-8065-4a0d-a6cf-6d0468fed0dc","added_by":"auto","created_at":"2024-10-15 07:36:24","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":398597,"visible":true,"origin":"","legend":"\u003cp\u003eContour plot \u0026amp; 3D surface plot of RSM In\u003cem\u003e vitro\u003c/em\u003epermeation\u003c/p\u003e","description":"","filename":"4.png","url":"https://assets-eu.researchsquare.com/files/rs-4761605/v1/f8e9505b4469999c3d58abf1.png"},{"id":66649531,"identity":"056fef62-8807-437f-8e22-f5b3451f0cee","added_by":"auto","created_at":"2024-10-15 07:28:24","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":279431,"visible":true,"origin":"","legend":"\u003cp\u003eOverlay plot for validation for optimized batch\u003c/p\u003e","description":"","filename":"5.png","url":"https://assets-eu.researchsquare.com/files/rs-4761605/v1/75e82836b0c89bb2ce255064.png"},{"id":66650556,"identity":"80a89204-8b03-4d27-903e-b769c23661f0","added_by":"auto","created_at":"2024-10-15 07:36:24","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":170964,"visible":true,"origin":"","legend":"\u003cp\u003eGraphical representation of \u003cem\u003ein vitro\u003c/em\u003e release of RTG\u003c/p\u003e","description":"","filename":"6.png","url":"https://assets-eu.researchsquare.com/files/rs-4761605/v1/3cd8ea09e8e46d8e1c5f8dda.png"},{"id":66650554,"identity":"3acb2925-d94a-4258-98e5-c38d4e9736c0","added_by":"auto","created_at":"2024-10-15 07:36:24","extension":"png","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":217624,"visible":true,"origin":"","legend":"\u003cp\u003eGraphical representation of \u003cem\u003ein vitro\u003c/em\u003e release of RSM\u003c/p\u003e","description":"","filename":"7.png","url":"https://assets-eu.researchsquare.com/files/rs-4761605/v1/f2353a4dac901a61c60bc4ec.png"},{"id":66650555,"identity":"d52f3388-14df-458e-980b-baabe5020b35","added_by":"auto","created_at":"2024-10-15 07:36:24","extension":"png","order_by":8,"title":"Figure 8","display":"","copyAsset":false,"role":"figure","size":101638,"visible":true,"origin":"","legend":"\u003cp\u003eGraphical representation of \u003cem\u003eEx vivo\u003c/em\u003e permeation of RTG through the rat skin\u003c/p\u003e","description":"","filename":"8.png","url":"https://assets-eu.researchsquare.com/files/rs-4761605/v1/ebd87af3689290fb98556370.png"},{"id":66649538,"identity":"06ee425d-336e-4c6c-baa0-5cd523054f27","added_by":"auto","created_at":"2024-10-15 07:28:25","extension":"png","order_by":9,"title":"Figure 9","display":"","copyAsset":false,"role":"figure","size":73877,"visible":true,"origin":"","legend":"\u003cp\u003eGraphical representation of \u003cem\u003eEx vivo\u003c/em\u003e permeation of RSM through the rat skin\u003c/p\u003e","description":"","filename":"9.png","url":"https://assets-eu.researchsquare.com/files/rs-4761605/v1/637411a1c36df74ac9c8c77e.png"},{"id":66651924,"identity":"8567fc37-2a6f-40cf-9d9f-cc01c2069afa","added_by":"auto","created_at":"2024-10-15 07:44:24","extension":"png","order_by":10,"title":"Figure 10","display":"","copyAsset":false,"role":"figure","size":1716505,"visible":true,"origin":"","legend":"\u003cp\u003eResults of skin irritancy for animals\u003c/p\u003e","description":"","filename":"10.png","url":"https://assets-eu.researchsquare.com/files/rs-4761605/v1/12af6bd2ca0caab9483b1432.png"},{"id":66649535,"identity":"da19b549-67eb-4017-ae68-59fe580ef9c1","added_by":"auto","created_at":"2024-10-15 07:28:24","extension":"png","order_by":11,"title":"Figure 11","display":"","copyAsset":false,"role":"figure","size":202983,"visible":true,"origin":"","legend":"\u003cp\u003eFTIR spectra of Transferosomal Patch of RTG: (A) 0 day, (B) 30\u003csup\u003eth\u003c/sup\u003e day,(C) 60\u003csup\u003eth\u003c/sup\u003e day, and (D) 90\u003csup\u003eth\u003c/sup\u003e\u0026nbsp; day\u003c/p\u003e","description":"","filename":"11.png","url":"https://assets-eu.researchsquare.com/files/rs-4761605/v1/cd054f3cc9317f72591a109c.png"},{"id":66649537,"identity":"8bacfdca-8ab1-4798-bd6d-f1ed44e6c954","added_by":"auto","created_at":"2024-10-15 07:28:24","extension":"png","order_by":12,"title":"Figure 12","display":"","copyAsset":false,"role":"figure","size":277299,"visible":true,"origin":"","legend":"\u003cp\u003eFTIR spectra of Transferosomal Patch of RSM: (A) 0 day, (B) 30\u003csup\u003eth\u003c/sup\u003e day, (C) 60\u003csup\u003eth\u003c/sup\u003e day, and (D) 90\u003csup\u003eth\u003c/sup\u003e\u0026nbsp; day\u003c/p\u003e","description":"","filename":"12.png","url":"https://assets-eu.researchsquare.com/files/rs-4761605/v1/dd7b57a83f58bb10ed0cfe11.png"},{"id":66655126,"identity":"c3f3c0f9-5bdc-4b47-bc5f-a2b5a9bd412f","added_by":"auto","created_at":"2024-10-15 08:08:43","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":7943718,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4761605/v1/787e1e81-a9d4-4938-891a-13268207a554.pdf"},{"id":66651923,"identity":"1cfd0dd1-e236-4c47-8683-d24d324327f6","added_by":"auto","created_at":"2024-10-15 07:44:24","extension":"jpg","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":197488,"visible":true,"origin":"","legend":"","description":"","filename":"Graphicalab.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4761605/v1/ea43e9aa0c89b2ed471a5143.jpg"}],"financialInterests":"","formattedTitle":"\u003cp\u003eTransferosomal Formulation of Rotigotine Hcl and Rasagiline Mesylate: a Step Towards Minimally Invasive Parkinson's Disease Therapy\u003c/p\u003e","fulltext":[{"header":"1 Introduction","content":"\u003cp\u003eParkinson\u0026rsquo;s disease (PD) is a clinical syndrome that was introduced by James Parkinson in 1817. The disease exhibits essential symptoms like rest tremors, rigidity, bradykinesia, instability of posture, and a diversity of other motor and non-motor symptoms[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. The scientific community is paying more attention to age-related disorders like PD as the world's population ages and lives longer. The fastest-growing of these neurological illnesses is PD, which is currently the main cause of disability in the world. A potential \"PD Epidemic\" is suggested by the World Burden of Disease Study's prognosis that the number of PD cases will double from 7\u0026nbsp;million in 2015 to 13\u0026nbsp;million in 2040[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. The majority of the treatments for PD include surgery and medications. The surgical approach includes deep brain stimulation, focused ultrasound, and cell replacement therapies that are invasive, while the medication includes levodopa, which is combined with carbidopa or benderizine, aromatic acid decarboxylase inhibitors, an anticholinergics amantadine, MAOIs, COMTIs, dopamine agonists [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e][\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. Adverse effects of the medication include nausea and vomiting, orthostatic hypotension, sedation, confusion, sleep disturbance, hallucinations, and dyskinesias. It should not be used in patients with renal impairment[\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eRotigotine HCL (RTG) is a dopamine receptor agonist approved for the treatment of idiopathic PD in several countries. The pharmacologically active form of RTG is its unconjugated parent drug[\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e], which binds to dopamine receptors to produce its effects, and Rasagiline mesylate (RSM), an irreversible propargylamine-based MAO B inhibitor, was approved for the treatment of idiopathic Parkinson's disease in May 2006; the US Federal Drug Administration (FDA) followed suit[\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. RSM is an irreversible inhibitor of MAO-B that selectively binds to and permanently deactivates this enzyme, leading to increased dopamine levels in the striatum and improved Parkinson's symptoms. Both thugs are from BCS classes II and III, respectively[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e].Many researcher prepared formulation by altering the route of administration and changing formulation to get better effect[\u003cspan additionalcitationids=\"CR10 CR11 CR12 CR13 CR14 CR15\" citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. The RSM is administered via a transdermal patch and is available in different strengths. Compared to oral therapy, transdermal delivery eliminates variables affecting gut absorption and bypasses the first-pass effects of the liver[\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. It provides continuous delivery, maintaining stable plasma drug concentrations over 24 hours with just one daily application. Transdermal delivery is also useful in perioperative and intensive care settings. On the other hand, RSM is available in oral tablet form with different strengths. Several factors, including the presence of hepatic first-pass metabolism, negative side effects, the rejection of invasive treatments, and poor patient compliance, make it difficult to obtain an effective, successful therapeutic therapy. Hence, numerous drug delivery methods have been researched and developed over the years to address these issues[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. Transdermal delivery systems, which are minimally invasive and have no first-pass effects, are one intriguing strategy. Yet it is important to address the skin's barrier function, which hinders or stops medicinal substances from being delivered transdermally[\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. The problem has been solved by employing nanoencapsulation with lipidic nanosystems, such as liposomes, SLN, NLC, etc[\u003cspan additionalcitationids=\"CR20 CR21 CR22\" citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. These carriers promote medication delivery through the skin: attachment to fusion with the stratum corneum's Shahd matrix, which increases drug partitioning into the skin, and lipid exchange between the liposomal membrane and cell membrane[\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e] which makes it easier for the drug to diffuse across membranes, but the drawbacks that are also present in such lipidic carriers are inadequate hydrophilic drug encapsulation efficiency, an unstable leaky behavior, and a brief half-life. The drug is then transferred directly from the vesicles to the skin surface. The newly introduced cutting-edge medication carriers for skin are called transferosomes, which can transport large molecules through intact mammalian tissues. A transferosome can instinctively penetrate skin and transport drugs from the application to the target area. The transferosome carriers are composed of hydrophilic and hydrophobic moieties, making them a unique class of drug delivery system that can carry therapeutics with various BCS classes of drugs. The extraordinary deformability and elasticity of transferosomes allow them to pass through skin barrier constraints that are 5 to 10 times smaller than the diameter of vesicles. Regardless of the size, molecular weight, polarity, or structure of the agents they are carrying, transferosomes are incredibly adaptable and effective[\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. In this research, an attempt has been made to prepare transferosome patches of both the drugs of different BCS classes, RTG (BCS class II) and RSM (BCS class III). RSM is a selective inhibitor of the enzyme MAO-B, which is responsible for the degradation of dopamine in the brain. On the other hand, RTG HCL is a dopamine agonist that ultimately raises the levels of dopamine in the brain. The RSM can attract and interact with water, and when it is in the form of transferosomes, it enables the drug to get through the blood-brain barrier. These transferosomes are very flexible vesicles that prevent the activeitransferasesB enzyme, resulting in a decrease in the breakdown of dopamine. Additionally, RTG HCL is responsible for increasing the concentration of dopamine. Ultimately, the therapy for Parkinson's disease will result in an elevated concentration of dopamine in the brain. Ultimately prepared formulation was evaluated with different parameters to check the effects of both drugs in the \u003cem\u003ein vivo\u003c/em\u003e study.\u003c/p\u003e"},{"header":"2 Materials and method","content":"\u003cp\u003eRTG was kindly gifted by Neuland Laboratory Mumbai, and RSM was procured from Benzchem Enterprise Vadodara.\u003c/p\u003e \u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003e2.1 Materials\u003c/h2\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e2.2 Method of preparation of transferosome Patches\u003c/h2\u003e \u003cp\u003eTransferosome patches were prepared by suspension homogenize followed by the casting method. To brief, Transferosomes of both drugs were prepared with the thin film hydration method as reported by Patel Shivani et al.[\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. To prepare the polymeric solution of an appropriate quantity of ethylcellulose (EC), HPMC K4M, Eudragit RS 100, and Eudragit RL 100, Mix all the solid ingredients in a beaker and add 7.5 ml of methanol and 7.5 ml of isopropyl alcohol dropwise, stirring until a homogeneous solution is obtained. After getting the homogenous solution, add a transferosome solution equivalent to 1 mg of each drug to this solution, add 0.6 ml of dibutyl phthalate, and again allow for homogenous mixing. Cast this polymeric solution on a backing membrane and allow it to dry in a preheated hot air oven at 60\u0026deg;C for 2 hours by covering the petri dish with an inverted funnel. Store the patches at room temperature in a dry place.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003e2.3 Optimization of transdermal Patches\u003c/h2\u003e \u003cp\u003eAfter the literature survey and preliminary trials, patches were optimized by applying a central composite design. In optimization design, dependent variables are selected at three levels, and two variables are selected. The independent variables are the (A) amount of Eudragit R, (B) amount of Eudragit RL, and (C) amount of HPMC K4M, and the dependent variables are (X1) percent drug release and (X2) tensile strength. The study matrix of central composite design with coded terms and actual terms is given in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eMatrix of central composite design with coded and actual values for optimization of transdermal patches\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"7\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eBatch\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eConcentration of Eudragit RS (mg)\u003c/p\u003e \u003cp\u003e(A)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eConcentration of Eudragit RL (mg)\u003c/p\u003e \u003cp\u003e(B)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eConcentration of HPMC K4M (mg)\u003c/p\u003e \u003cp\u003e(C)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003eActual value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eY1\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eY2\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003eY3\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e1\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e-1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e-1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e200\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e2\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e32.96\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e150\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e150\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e4\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1.68\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e150\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e5\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e117.04\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e150\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e6\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e-1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e-1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e150\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e7\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e-1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e-1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e-1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e8\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e-1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e-1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e32.96\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e150\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e9\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e-1.68\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e10\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.68\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e200\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e11\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e-1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e117.04\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e150\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e12\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1.68\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e234.09\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e13\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e-1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e200\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e14\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e-1.68\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e150\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e15\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e16\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e200\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e17\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e-1.68\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e18\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e150\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e19\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e-1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e150\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e20\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e65.91\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"3 Evaluation of Transdermal Patches","content":"\u003cdiv id=\"Sec7\"\u003e\n \u003ch2\u003e3.1 Thickness\u003c/h2\u003e\n \u003cp\u003eThe thickness of the patches is essential for their brittleness. Thickness is dependent on the area of the Petri plate to be spread. The thickness of the patches was measured using a screw gauge at six different points. Values were recorded, and the mean with standard deviation (center and corners), a screw gauge, and a mean value of five locations were used as a film thickness[\u003cspan\u003e26\u003c/span\u003e].\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec8\"\u003e\n \u003ch2\u003e3.2 Weight variation\u003c/h2\u003e\n \u003cp\u003eThe weight variation assessment was done by weighing 10 patches that were randomly selected on a digital balance in triplicate for each patch. The average weights were calculated, and the standard deviation from the average weights was measured[\u003cspan\u003e27\u003c/span\u003e].\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec9\"\u003e\n \u003ch2\u003e3.3 Folding endurance\u003c/h2\u003e\n \u003cp\u003eThe folding endurance is defined as the number of folds required to break any polymeric patch of RTG and RSM-loaded transferosomal transdermal patches. It was measured manually by folding the patch (2 \u0026times; 2 cm) on the same site until it was broken. The number of counts required to break the patch on the same site is considered the folding endurance of the patch. Repeat this procedure three times for a single patch and record the value with means. Three patches of each type were taken for the test.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec10\"\u003e\n \u003ch2\u003e3.4 Tensile strength\u003c/h2\u003e\n \u003cp\u003eThe tensile strength of each patch was measured using an in-house modified assembly, as shown in Fig. \u003cspan\u003e1\u003c/span\u003e. A patch of 2\u0026times;2 cm was used for the study. One end of the patch was fixed to the surface, and the other end was attached to the thread to which weight was applied. (One end of the thread was fixed with a patch, and the other end of the thread is attached to the assembly, which holds the weight to be applied.) Record the weight at which the patch starts to break and calculate it with the given equation.\u003c/p\u003e\n \u003cdiv id=\"Equa\"\u003e\n \u003cdiv id=\"FileID_Equa\" name=\"EquationSource\"\u003e$$\\:\\mathbf{T}\\mathbf{e}\\mathbf{n}\\mathbf{s}\\mathbf{i}\\mathbf{l}\\mathbf{e}\\:\\mathbf{s}\\mathbf{t}\\mathbf{r}\\mathbf{e}\\mathbf{n}\\mathbf{g}\\mathbf{t}\\mathbf{h}=\\:(\\mathbf{b}\\mathbf{r}\\mathbf{e}\\mathbf{a}\\mathbf{k}\\:\\mathbf{f}\\mathbf{o}\\mathbf{r}\\mathbf{c}\\mathbf{e}/\\mathbf{a}\\:\\times\\:\\:\\mathbf{b})\\:\\times\\:\\:(1+\\mathbf{L}/\\mathbf{I})\\:$$\u003c/div\u003e\n \u003c/div\u003e\n \u003cp\u003eWhere a is width, b is thickness, L is length, and I is elongation\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec11\"\u003e\n \u003ch2\u003e3.5 Drug content uniformity\u003c/h2\u003e\n \u003cp\u003eThe drug content uniformity was performed to check the uniform distribution of RTG and RSM in transferosome-loaded patches. The amount of drugs contained in the patch was determined by dissolving Each patch of 2\u0026times;2 cm was cut from different sections, weighed in methanol, kept for stirring by using a magnetic stirrer for 24 hours, and filtered. Appropriate dilutions were made with phosphate buffer, and the resulting solution was filtered through a Watman filter paper. Drug content was measured spectrophotometrically at a \u0026lambda;max at 239 nm and 273 nm respectively with a linear equation[\u003cspan\u003e28\u003c/span\u003e].\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec12\"\u003e\n \u003ch2\u003e3.6 Moisture content study\u003c/h2\u003e\n \u003cp\u003eMoisture content is important to check as it is directly applied to the skin membrane. The prepared patches were weighed and kept in a desiccator containing activated silica at room temperature for 24 hours. The individual films were weighed every alternate day until a constant weight was achieved. The percentage of moisture content was calculated by determining the difference between the initial and final weights for the final weight[\u003cspan\u003e28\u003c/span\u003e]. The moisture content was calculated by the following equation.\u003c/p\u003e\n \u003cdiv id=\"Equb\"\u003e\n \u003cdiv id=\"FileID_Equb\" name=\"EquationSource\"\u003e\u003cimg src=\"https://myfiles.space/user_files/122228_c8a1650c59388082/122228_custom_files/img1726665081.png\"\u003e\u003cbr\u003e\u003c/div\u003e\n \u003c/div\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec13\"\u003e\n \u003ch2\u003e3.7 Elongation\u003c/h2\u003e\n \u003cp\u003eThe percentage of elongation of the films was measured by fixing one end of the film between the two iron screens to support the film, and another was connected to the paper holder in which the hook was inserted. A thread was tied to this hook, passed over the pulley, and a small pan was attached to the other end to hold the weight. A small pointer was attached to the thread, which travels over the scale affixed to the base plate. The elongation was determined by recording the distance traveled by the pointer before the film\u0026apos;s break on the scale[\u003cspan\u003e29\u003c/span\u003e]. The elongation was determined using the following formula:\u003c/p\u003e\n \u003cdiv id=\"Equc\"\u003e\n \u003cdiv id=\"FileID_Equc\" name=\"EquationSource\"\u003e$$\\:\\varvec{\\%}\\:\\varvec{E}=(L1-L2)/L2*100$$\u003c/div\u003e\n \u003c/div\u003e\n \u003cp\u003ewhere L1 is the final length of the patch, and L2 is the initial length of the patch.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec14\"\u003e\n \u003ch2\u003e3.8 \u003cem\u003eIn vitro\u003c/em\u003e drug release studies\u003c/h2\u003e\n \u003cp\u003eThe \u003cem\u003ein vitro\u003c/em\u003e drug release profile is utilized as a scientific tool to optimize the transferosomal formulation by providing fundamental information on formulation design and specifics on the release mechanism and kinetics. An \u003cem\u003ein vitro\u003c/em\u003e drug release study was performed using the Franz diffusion apparatus with a phosphate buffer pH of 7.4. To perform the \u003cem\u003ein vitro\u003c/em\u003e drug release of transdermal matrix-type patches, The MWCO of cellophane membranes typically falls in the range of approximately 6,000 to 14,000 Daltons. The transdermal film was set on top in the donor compartment and covered with aluminum foil, while the membrane was positioned between the donor and receptor compartments of a diffusion cell. The receptor compartment was heated to 37\u0026thinsp;\u0026plusmn;\u0026thinsp;0.5\u0026deg;C, which is the average body temperature of an adult human, and allowed for continuous stirring with magnetic beads at 100 rpm speed on a hot plate magnetic stirrer. Samples were collected at various time intervals (0, 5, 10, 15, 20, and 25 hr.) and evaluated for drug content with UV-spectrophotometry. Following each sample withdrawal, an equal volume of phosphate buffer was added to the receptor phase[\u003cspan\u003e30\u003c/span\u003e].\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec15\"\u003e\n \u003ch2\u003e3.9 \u003cem\u003eEx vivo\u003c/em\u003e drug permeation studies\u003c/h2\u003e\n \u003cp\u003eThe ex vivo permeation studies were conducted using Franz diffusion cells and Wistar rat skin. For these experiments, full-thickness abdominal skin (with approx. thickness: 0.5 mm to 1.5 mm) samples from Wistar rats weighing between 200 and 250 grams were employed. Before the initiation of the study, the abdominal hair in the designated region was gently removed using an electric clipper, and the dermal side of the skin specimens underwent thorough cleansing with distilled water to remove any adhering tissues or blood vessels. Subsequently, the skin samples were allowed to soak in a phosphate buffer solution with a pH of 7.4 for one hour. This step was essential to ensure that the skin reached an equilibrium state in terms of moisture content and pH before the commencement of the experiment. Once the skin preparation was completed, transdermal patches (1 cm x 1 cm) were applied to the skin surface. To promote the uniform distribution of the diffusion across the skin surface, a magnetic stirrer equipped with a small magnetic bar was utilized. Throughout the experiment, precise temperature control was maintained within the Franz diffusion cell at 37\u0026thinsp;\u0026plusmn;\u0026thinsp;0.5\u0026deg;C, achieved through the use of a thermostatically regulated heater. At predefined time intervals, 5 ml of sample was withdrawn. To maintain a sink condition, fresh phosphate buffer with a pH of 7.4 was added. The samples were subsequently filtered using the Whatman filter paper and subjected to analysis through a developed and validated simultaneous first-order derivative method employing a UV-spectrophotometer[\u003cspan\u003e31\u003c/span\u003e]. The percentage of drug permeated was calculated based on these analyses.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec16\"\u003e\n \u003ch2\u003e3.10 \u003cem\u003eIn vivo\u003c/em\u003e skin irritancy studies\u003c/h2\u003e\n \u003cp\u003eAnimal experimentation serves as a pivotal component in the assessment of formulation efficacy and potential toxicity. In this context, an animal study was conducted to compare the effects and irritancy of two distinct formulations. The experimental protocol received ethical approval from the Institutional Animal Ethical Committee at Parul Institute of Pharmacy and Research, India, bearing reference no. \u003cstrong\u003ePIPR 984/2022/02.\u003c/strong\u003e Following the guidelines established by the Organisation for Economic Co-operation and Development (OECD), specifically OECD 404, the dermal toxicokinetic study necessitated the selection of animals of either sex aged between 6 and 12 weeks, and groups made as shown in Table \u003cspan\u003e4\u003c/span\u003e. Before testing, the dorsal area of the trunk of the test animals was carefully clipped. Shaving was performed approximately 24 hours before initiation of the study, with meticulous attention to prevent any skin abrasion that could potentially influence skin permeability[\u003cspan\u003e32\u003c/span\u003e].\u003c/p\u003e\n \u003cp\u003eApproximately 10% of the body surface area was cleared to ensure optimal application of the test substance. Subsequently, all animals underwent a comprehensive examination for the presence of erythema and edema. These responses were meticulously assessed and documented at several time points, including 60 minutes 24, 48, and 72 hours following the removal of the test patches. Additionally, an immediate post-patch removal examination was conducted in one animal, with subsequent grading and documentation of dermal reactions.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec17\"\u003e\n \u003ch2\u003e3.11 Pharmacokinetic studies\u003c/h2\u003e\n \u003cp\u003ePharmacokinetic studies assume paramount importance in early-stage drug development due to their capacity to unravel the Absorption, Distribution, Metabolism, and Excretion (ADME) properties of pharmaceutical compounds. These investigations yield critical insights into various aspects, including the potential impact of food interactions, drug-drug interactions, and organ impairment on drug disposition. Pharmacokinetics constitutes a pivotal domain of scientific inquiry, offering invaluable data regarding the intricate behavior of molecules within biological organisms. The experimental protocol underwent rigorous scrutiny and attained ethical approval from the Institutional Animal Ethical Committee at Parul Institute of Pharmacy and Research, India, bearing the reference number PIPR 984/2022/02/17.In strict conformance with the guidelines stipulated by the Organization for Economic Co-operation and Development (OECD) 417, the dermal toxicokinetic study necessitated the selection of twelve animals, disregarding gender, aged within the range of 6 to 12 weeks. In the preparatory phase, meticulous fur clipping from the dorsal trunk area of the test animals occurred immediately before the onset of the study. Shaving procedures were executed approximately 24 hours before the study initiation, with utmost care taken to prevent any potential skin abrasions that could influence skin permeability. Approximately 10% of the body surface area was intentionally cleared to ensure precise application of the transdermal patch containing the test substance.\u003c/p\u003e\n \u003cp\u003eFollowing patch application, blood samples were systematically collected at predefined intervals, specifically at 0, 1, 2, 3, 4, 6, 12, 18, and 24 hours post-application. The isolation of plasma from the collected blood samples involved centrifugation at 10,000 revolutions per minute for 15 minutes, with temperature control maintained at 20\u0026deg;C. Subsequently, quantification of plasma concentrations was performed using a meticulously developed and rigorously validated High-Performance Liquid Chromatography (HPLC) bioanalytical method (unpublished work). Pharmacokinetic parameters were then derived based on the acquired datasets of stability Studies\u003c/p\u003e\n \u003cp\u003eThe stability assessment of the formulation was conducted under two distinct environmental conditions. Various parameters including the percentage of \u003cem\u003ein vitro\u003c/em\u003e drug release, percentage of drug content, tensile strength, and Fourier-transform infrared (FTIR) spectroscopy analysis were meticulously evaluated at designated time points encompassing days 0, 30, 60, and 90[\u003cspan\u003e33\u003c/span\u003e].\u003c/p\u003e\n\u003c/div\u003e"},{"header":"4 Results and Discussion","content":"\u003cdiv id=\"Sec19\" class=\"Section2\"\u003e \u003ch2\u003e4.1 Statistical analysis\u003c/h2\u003e \u003cp\u003eAll the statistical calculation was performed using a DOE. Data are expressed as mean\u0026thinsp;\u0026plusmn;\u0026thinsp;S.D. Data were analyzed statistically using analysis of variance (ANOVA). A p-value less than 0.05 was considered statistically significant[\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eOptimization of transferosomal patches was performed using a Central Composite Design. A total of 20 batches were suggested by the Design of Experiments software. These batches underwent evaluations for several parameters, including thickness uniformity, folding endurance, drug content uniformity, tensile strength, and ex-vivo drug diffusion. The acquired responses were then analyzed using Design Expert software and fitted into various polynomial models, such as linear, two-factor interaction (2FI), cubic, and quadratic models. A quadratic model was proposed for both the in-vitro drug release (Y1) and tensile strength (Y2) responses.\u003c/p\u003e \u003cp\u003eThe F16 batch was selected as the optimized batch because it demonstrated good in-vitro drug release and tensile strength, as shown in Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e. As the concentrations of the selected independent variables increased, there was a decrease in in-vitro drug release. The greater density produced a more compact matrix, which restricted the movement and diffusion of the drug molecules, thereby slowing down the drug release. Conversely, as the concentration of independent variables increased, there was an increase in tensile strength. HPMCK4M and Eudragit contributed to the mechanical strength and flexibility of the formulation, thus potentially improving its folding endurance. However, during studies, it was observed that at optimum concentration results are better. The F16 batch shows 93.79% In-Vitro drug release of RTG and 91.82% of RSM. Which is the maximum %CDR amongst all batches. The Tensile strength demonstrated 0.1257035 kg/cm2. The responses showed the opposite effect beyond optimized concentration. Hence F16 batch was selected as it showed better results than other batches. Beyond optimized concentrations, \u003cem\u003eIn vitro\u003c/em\u003e drug release started to decrease.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eMeasures and Responses of Optimization of Transferosomal Patch\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"7\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBatch\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eA\u003c/p\u003e \u003cp\u003e(Amt of eudragit RS 100)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eB\u003c/p\u003e \u003cp\u003e(Amt of eudragit RL 100)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eC\u003c/p\u003e \u003cp\u003e(Amt of HPMCK4M)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eY1\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eY2\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003eY2\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e74.74\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e72.47\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.067208\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e67.79\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e65.52\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.062842\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e63.34\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e58.82\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.061837\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e66.76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e62.68\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.145369\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e200\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e87.69\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e80.75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.096352\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e200\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e61.68\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e58.26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.097145\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e200\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e71.34\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e67.62\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.186718\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e200\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e72.73\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e68.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.284874\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e32.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e150\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e76.84\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e73.82\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.083913\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e117.04\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e150\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e66.78\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e64.04\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.224036\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e32.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e150\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e75.14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e71.61\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.085506\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e117.04\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e150\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e62.99\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e60.87\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.229321\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e65.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e68.31\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e63.49\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.025274\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e234\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e73.74\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e71.23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.183092\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e150\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e93.76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e91.54\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.125506\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e16\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003e75\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003e75\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e150\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e93.79\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e91.82\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e\u003cb\u003e0.125703\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e17\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e150\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e93.03\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e91.14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.125818\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e150\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e93.30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e91.69\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.125884\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e150\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e93.06\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e91.47\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.125101\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e150\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e93.7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e91.39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.1252\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cdiv id=\"Sec20\" class=\"Section3\"\u003e \u003ch2\u003e4.1.1 Statistical interpretation of Tensile strength\u003c/h2\u003e \u003cp\u003eThe R-squared value for tensile strength is 0.9745, as shown by the summary statistics for tensile strength provided by the Design Expert software. The main effects are statistically significant, according to the quadratic model. The terms A, B, and C are considered to be the main effects because the value of \"Prob\u0026thinsp;\u0026gt;\u0026thinsp;F\" is less than 0.0500. On the other side, values higher than 0.1000 imply that the model terms are not important. The F-value for the model, which is 42.503, indicates that the model is significant. The p-value of AB is less than 0.05 which indicates interaction of eudragit RS 100 and eudragit RL 100 is significant same way p-value for BC is also less than 0.05 which indicates that eudragit RL 100 and HPMCK4M shows a significant interaction. The polynomial equation suggests the negative effect of A and B and the positive effect of C term on tensile strength.\u003c/p\u003e \u003cp\u003e \u003cb\u003eFinal Equation in Terms of Coded Factors\u003c/b\u003e:\u003c/p\u003e \u003cp\u003eFull Polynomial Equation\u003c/p\u003e \u003cp\u003eTensile strength\u0026thinsp;=\u0026thinsp;+\u0026thinsp;91.52\u0026ndash;3.01 * A -2.74 * B\u0026thinsp;+\u0026thinsp;2.10 * C\u0026thinsp;+\u0026thinsp;4.27* A * B -+1.70 * B * C -8.39 * C\u003csup\u003e2\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eReduce Polynomial Equation\u003c/p\u003e \u003cp\u003eTensile strength = -3.01 * A -2.74 * B\u0026thinsp;+\u0026thinsp;2.10 * C\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec21\" class=\"Section3\"\u003e \u003ch2\u003e4.1.2 Statistical interpretation of RTG in vitro release\u003c/h2\u003e \u003cp\u003eThe R-Squared \u003cem\u003eIn Vitro\u003c/em\u003e drug release is 0.9805, as shown by the summary statistics for In-Vitro drug release provided by the Design Expert software. The main effects are statistically significant, according to the quadratic model. The terms A, B, and C are considered to be the main effects because the value of \"Prob\u0026thinsp;\u0026gt;\u0026thinsp;F\" is less than 0.0500. On the other side, values higher than 0.1000 imply that the model terms are not important. The F-value for the model, which is 55.909304, indicates that the model is significant (Table\u0026nbsp;4.25). The p value of AB is less than 0.05 which indicates interaction of eudragit RS 100 and eudragit RL 100 is significant same way the value for AC is also less than 0.05 which indicates that eudragit RS 100 and HPMCK4M shows significant interaction. The polynomial equation suggests the negative effect of A and B and the positive effect of C term on \u003cem\u003ein vitro\u003c/em\u003e drug release.\u003c/p\u003e \u003cp\u003e \u003cb\u003eFinal Equation in Terms of Coded Factors for RTG\u003c/b\u003e:\u003c/p\u003e \u003cp\u003eFull Polynomial equation\u003c/p\u003e \u003cp\u003e% \u003cem\u003eIn-Vitro\u003c/em\u003e drug release\u0026thinsp;=\u0026thinsp;+\u0026thinsp;93.49\u0026ndash;3.30 * A -2.79 * B\u0026thinsp;+\u0026thinsp;2.19 * C\u0026thinsp;+\u0026thinsp;4.72 * A * B -2.64 * A * C -7.36 * A\u003csup\u003e2\u003c/sup\u003e -8.33 * B\u003csup\u003e2\u003c/sup\u003e -7.64 * C\u003csup\u003e2\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eReduce polynomial equation\u003c/p\u003e \u003cp\u003e% \u003cem\u003eIn-Vitro\u003c/em\u003e drug release\u0026thinsp;=\u0026thinsp;+\u0026thinsp;93.49\u0026ndash;3.30 * A -2.79 * B\u0026thinsp;+\u0026thinsp;2.19 * C\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec22\" class=\"Section3\"\u003e \u003ch2\u003e4.1.3 Statistical interpretation of in vitro release\u003c/h2\u003e \u003cp\u003eThe R-squared value for the Response Surface Methodology \u003cem\u003eIn Vitro\u003c/em\u003e drug release is 0.9919, as indicated by the summary statistics provided by the Design Expert software. The quadratic model shows that the main effects are statistically significant. The terms A, B, and C are considered the main effects because the \"Prob\u0026thinsp;\u0026gt;\u0026thinsp;F\" values are less than 0.0500. On the other hand, values greater than 0.1000 suggest that the model terms are not important. The model's F-value of 136.54 indicates that the model is significant.\u003c/p\u003e \u003cp\u003eThe p-value, which is less than 0.05, suggests a significant interaction between Eudragit RS 100 and Eudragit RL 100. Similarly, the p-value for the interaction between Eudragit RS 100 and HPMC K4M is also less than 0.05, indicating a significant interaction. The polynomial equation suggests a negative effect of factors A and B and a positive effect of factor C on in-vitro drug release.\u003c/p\u003e \u003cp\u003e \u003cb\u003eFinal Equation in Terms of Coded Factors for RSM\u003c/b\u003e \u003c/p\u003e \u003cp\u003eFull Polynomial Equation\u003c/p\u003e \u003cp\u003e% \u003cem\u003eIn-Vitro\u003c/em\u003e drug release\u0026thinsp;=\u0026thinsp;+\u0026thinsp;91.52\u0026ndash;3.01 * A -2.74 * B\u0026thinsp;+\u0026thinsp;2.10 * C\u0026thinsp;+\u0026thinsp;4.27 * A * B -2.31 * A * C\u0026thinsp;+\u0026thinsp;1.70 * B * C -7.83 * A\u003csup\u003e2\u003c/sup\u003e-8.78 * B\u003csup\u003e2\u003c/sup\u003e -8.39 * C\u003csup\u003e2\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eReduce polynomial Equation\u003c/p\u003e \u003cp\u003e% \u003cem\u003eIn Vitro\u003c/em\u003e drug release\u0026thinsp;=\u0026thinsp;+\u0026thinsp;91.52\u0026ndash;3.01 * A -2.74 * B\u0026thinsp;+\u0026thinsp;2.10 * C\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eThe overlay plot for the formulation was obtained from design expert 7. In the overlay plot, the yellow region indicates the area in which optimized formulation can be formulated. Hence the yellow portion indicates values of A, B \u0026amp; C which were near to the values of formulation F16. The values of responses \u003cem\u003ein vitro\u003c/em\u003e drug release and Tensile strength of formulation F16 which is desirable and good compared to other batches. Therefore, the formulation F16 was taken as an optimized batch of RTG \u0026amp; RSM transdermal patch.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eResults for validation batches\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eResponse\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003ePredicted results\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eObserved results\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eMean\u0026thinsp;\u0026plusmn;\u0026thinsp;SD\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% \u003cem\u003eIn vitro\u003c/em\u003e Drug Release RTG\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e94.1277%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e94.01\u0026thinsp;\u0026plusmn;\u0026thinsp;0.002%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e% \u003cem\u003eIn vitro\u003c/em\u003e Drug Release RSM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e92.0207%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e92.23\u0026thinsp;\u0026plusmn;\u0026thinsp;0.0103%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTensile strength\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.130189 kg/cm2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0.13143 kg/cm2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec23\" class=\"Section2\"\u003e \u003ch2\u003e4.2 Results of Optimization of Transdermal Patches\u003c/h2\u003e \u003cdiv id=\"Sec24\" class=\"Section3\"\u003e \u003ch2\u003e4.2.1 Thickness\u003c/h2\u003e \u003cp\u003ethe observed augmentation in patch thickness with increasing HPMCK4M content is a consequence of the enhanced availability of polymeric chains and the subsequent formation of a denser polymeric network within the patch matrix. This phenomenon underscores the pivotal role of HPMCK4M in influencing the physical attributes and characteristics of the transdermal patches. Weight variation For the weight variation patches were randomly selected and weighed on analytical balance thrice. Recorded values were then calculated for mean and standard deviation values.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec25\" class=\"Section3\"\u003e \u003ch2\u003e4.2.2 Folding endurance\u003c/h2\u003e \u003cp\u003eThe folding endurance of the patches was found to be 111 and 109 respectively for both drugs. In essence, HPMCK4M and Eudragit polymers play a pivotal role in bolstering the mechanical properties of the patch, ultimately contributing to its remarkable folding endurance. This, in turn, underscores their significance in ensuring the patch's functionality and integrity under diverse mechanical stresses.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec26\" class=\"Section3\"\u003e \u003ch2\u003e4.2.3 Tensile Strength\u003c/h2\u003e \u003cp\u003eThe acquired data revealed that the recorded tensile strength values for the two distinct patches under investigation were as follows: 0.13143 kg/cm\u0026sup2; and 0.1389 kg/cm\u0026sup2;, respectively. These values represent the force per unit area required to cause the patch to fracture or rupture when subjected to tensile forces. Higher tensile strength values signify increased resistance to stretching or pulling, which can be advantageous for ensuring the structural integrity and durability of the patch in various practical applications. The obtained results demonstrate the positive effect of independent variables on the response, namely the tensile strength of the patch. As the concentrations of HPMCK4M, Eudragit RS100, and Eudragit RL100 increase, the tensile strength also increases. This is due to the ability of HPMCK4M, Eudragit RS100, and Eudragit RL100 to modify the characteristics of the patch's polymer matrix. They enhance the matrix's cohesiveness and flexibility, thereby bolstering its mechanical strength. Consequently, the patch's tensile strength experiences an enhancement. It is well-established that HPMCK4M, Eudragit RS100, and Eudragit RL100 can reinforce polymeric matrices. When incorporated into a patch, they can function as fillers or reinforcers within the polymer matrix. The greater tensile strength results from the patch's heightened resistance to deformation and breakage, attributed to the presence of these reinforcing agents.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec27\" class=\"Section3\"\u003e \u003ch2\u003e4.2.4 Drug content uniformity\u003c/h2\u003e \u003cp\u003eThe drug content in different transdermal preparations containing RTG ranged from 98.3-102.1% and for RSM 97.7 to 101.6%. Notably, the transdermal film formulation labelabeledF16 demonstrated nearly 99.4% drug content of RSM and 101.9% drug content of RSM. The distribution of the drug within the transdermal films was uniform, and minimal drug loss occurred during or after the formulation process.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec28\" class=\"Section3\"\u003e \u003ch2\u003e4.2.5 Moisture content study\u003c/h2\u003e \u003cp\u003e \u003cem\u003eThe\u003c/em\u003e moisture content within the transdermal films was found to exhibit a range between 0.36% and 5.8%. Notably, an observable trend emerged with the increment of HPMC concentration, as it directly corresponded to an increase in the percentage of moisture content within the films. This phenomenon underscores the influence of HPMC concentration on the films' moisture-absorbing capacity.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec29\" class=\"Section3\"\u003e \u003ch2\u003e4.2.6 Elongation\u003c/h2\u003e \u003cp\u003eThe elongation properties of the two investigated patches were quantified and found to be 29 and 31, respectively. Notably, one of the components employed in the formulation, Hydroxypropyl Methylcellulose (HPMC), is a hydrophilic polymer frequently employed in pharmaceutical applications as a film-forming agent. HPMC imparts enhanced elasticity and flexibility to the formulation. Generally, the elongation characteristics of the material can be augmented by elevating the concentration of HPMC. This effect is attributed to HPMC's capability to generate a pliable film that can undergo stretching before experiencing fracture.\u003c/p\u003e \u003cp\u003eIn contrast, certain copolymers such as Eudragit RL and RS, which exhibit a greater hydrophobic propensity compared to HPMC, are commonly utilized in applications like enteric coatings or controlled-release systems. These Eudragit polymers, relative to HPMC, often demonstrate reduced elongation properties. They produce films characterized by diminished stretchability and increased stiffness.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec30\" class=\"Section3\"\u003e \u003ch2\u003e4.2.7 In vitro drug release of RSM and RTG\u003c/h2\u003e \u003cp\u003eThe results for the release of RTG are within the range of 61.68\u0026thinsp;\u0026plusmn;\u0026thinsp;0.941 to 93\u0026thinsp;\u0026plusmn;\u0026thinsp;0.479, while for RSM, it falls within the range of 58.26\u0026thinsp;\u0026plusmn;\u0026thinsp;0.317 to 91.82\u0026thinsp;\u0026plusmn;\u0026thinsp;0.293. Batch 16 is considered the optimized batch, as it exhibits a significant drug release for both RTG and RSM. Based on the in vitro release results of RTG and RSM, it can be inferred that an increase in the number of polymers leads to a decrease in the release of both drugs over a 24-h24 hours phenomenon is attributed to the presence of polymers such as HPMC, Eudragit RS, and Eudragit RL 100, which are commonly used in drug patches to regulate drug release. As the concentrations of these polymers increase, the overall polymer density in the patch also rises, resulting in a more compact matrix. This denser matrix restricts the movement and diffusion of drug molecules, thereby slowing down drug release.\u003c/p\u003e \u003cp\u003eAnother contributing factor to the decreased drug release in patches with higher polymer concentrations is the development of a thicker surface layer or barrier. At higher polymer concentrations, this physical barrier layer acts as an impediment, preventing the drug from diffusing out of the patch. The increased thickness of this layer further limits drug release, resulting in a slower release rate. HPMC, Eudragit RS 100, and Eudragit RL 100 can interact with drug molecules through various processes, such as hydrogen bonding or hydrophobic contact. Higher polymer concentrations increase the number of polymer chains available to interact with the drug. These interactions can result in stronger binding or association between the polymer and drug molecules, further contributing to the slowing of drug release. Figures\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003e and \u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003e provide graphical representations of the in vitro drug release results.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec31\" class=\"Section3\"\u003e \u003ch2\u003e4.2.8 Ex vivo drug permeation studies\u003c/h2\u003e \u003cp\u003eThe transdermal film formulation F16 demonstrated drug permeation rates of 92.73\u0026thinsp;\u0026plusmn;\u0026thinsp;0.054% for RTG and 84.87\u0026thinsp;\u0026plusmn;\u0026thinsp;0.002% for RSM within a 24-hour timeframe, as illustrated in Figs.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e8\u003c/span\u003e and \u003cspan refid=\"Fig9\" class=\"InternalRef\"\u003e9\u003c/span\u003e. The plotted graphs (% CDR vs. time) for the optimized batch indicated coefficient of determination (R\u0026sup2;) values of 0.9036 for RTG and 0.9445 for RSM, respectively, over the 24-hour duration. These results affirm that the transdermal formulation effectively releases the drug at an appropriate skin flux throughout the entire 24-hour period in which maximum drug release was found in RTG formulation which is more than 92%. Furthermore, the graphical representation of the cumulative drug concentration (%) permeating through the rat's abdominal skin over time suggested that the drug permeation follows zero-order kinetics. Additionally, the formulation exhibited significant release kinetics following the Higuchi model, with R\u0026sup2; values of 0.959 for RTG and 0.9372 for RSM. These findings underscore the formulation's adherence to the Higuchi model, indicating a controlled and consistent release pattern.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec32\" class=\"Section3\"\u003e \u003ch2\u003e4.2.9 Skin Irritancy studies\u003c/h2\u003e \u003cp\u003eTo comprehensively evaluate the potential effects of continuous transdermal patch usage on the skin, a skin irritancy test was meticulously conducted. The Draize method, a well-established approach for assessing skin irritation, was employed, utilizing a skin irritation index to systematically inspect and grade the results.\u003c/p\u003e \u003cp\u003eThe transdermal patch was applied to the skin of the experimental subjects for a few hours. During this period, a thorough examination of the rat's skin was conducted to detect any indicators of erythema (skin redness) or edema (swelling). Notably, the observations made during this initial 48-hour period, as depicted in Fig.\u0026nbsp;\u003cspan refid=\"Fig10\" class=\"InternalRef\"\u003e10\u003c/span\u003e and Table\u0026nbsp;\u003cspan refid=\"Tab4\" class=\"InternalRef\"\u003e4\u003c/span\u003e, revealed the absence of any erythematous or edematous symptoms. Building on these findings, the study was extended to a 72-hour timeframe. Remarkably, even after this prolonged duration of patch application, there remained no observable erythema or edematous symptoms on the skin. These consistently favorable results strongly suggest that the long-term usage of the transdermal patch containing RSM and RTG poses no discernible skin irritancy risks.\u003c/p\u003e \u003cp\u003eIn essence, the systematic assessment conducted through the Draize method, coupled with the extended observation period, provides robust evidence supporting the safety of prolonged and continuous usage of the RSM and RTG transdermal patch, with no indications of skin irritation.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab4\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 4\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eObservation of Skin Irritancy Studies\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"10\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c10\" colnum=\"10\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eGroups\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"8\" nameend=\"c10\" namest=\"c3\"\u003e \u003cp\u003eNo of animal\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eGroup 1: Normal control\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"8\" nameend=\"c10\" namest=\"c3\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eGroup 2: Treated with formulation\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"8\" nameend=\"c10\" namest=\"c3\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eEvaluation parameter\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e\u003cb\u003eObservation\u003c/b\u003e\u003c/p\u003e \u003cp\u003e\u003cb\u003eScore\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003eTime\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e1\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e2\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e\u003cb\u003e3\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cb\u003e4\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e\u003cb\u003e5\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e\u003cb\u003e6\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eErythema\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003eOedema\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eHour\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e0\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e0\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e\u003cb\u003e0\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cb\u003e0\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e\u003cb\u003e0\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e\u003cb\u003e0\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo erythema\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo oedema\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3\u003c/p\u003e \u003cp\u003e(min)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eVery slight erythema (barely perceptible)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eVery slight edema barely perceptible)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWell defined erythema\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSlight oedema\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eModerate to severe erythema\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eModerate oedema\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e48\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSevere erythema\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSevere oedema\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec33\" class=\"Section3\"\u003e \u003ch2\u003e4.2.10 In vivo pharmacokinetic studies\u003c/h2\u003e \u003cp\u003eThe application of the transferosomal patch was subjected to comprehensive pharmacokinetic analysis, comparing it with both a single dose of RSM nanoparticles following intravenous (i.v.) administration and Neupro. This evaluation was based on the analysis of plasma drug concentration-time profiles, as detailed in the pharmacokinetic parameters presented in Table\u0026nbsp;\u003cspan refid=\"Tab5\" class=\"InternalRef\"\u003e5\u003c/span\u003e. Upon patch administration, the initial plasma concentration values within the first 2\u0026ndash;3 hours fell below the lower limit of quantification defined by the analytical method. In contrast, the intravenous formulation of RSM exhibited a significantly faster initial drug release rate, reaching its peak plasma concentration promptly. Specifically, quantifiable plasma concentrations were achieved at 3 hours for RSM and 2 hours for RTG. The maximum observed plasma concentration (Cmax) was 199.3 ng/ml for RSM and 107.6 ng/ml for RTG. Furthermore, the time required to attain maximum plasma concentration was notably prolonged, taking 12 hours for RSM and 18 hours for RTG. The elimination half-life (t\u0026frac12;) values for RSM and RTG were observed to be 18 hours and 33 hours, respectively. These values, when compared with standard reference data provided in Table\u0026nbsp;\u003cspan refid=\"Tab5\" class=\"InternalRef\"\u003e5\u003c/span\u003e, indicate that both drugs exhibit extended half-lives when administered in the form of a transferosomal patch. Furthermore, a noteworthy increase in the area under the concentration-time curve (AUC), a critical pharmacokinetic parameter, was observed for both drugs. Specifically, the AUC of RSM increased six-fold, while that of RTG increased twelve-fold, signifying a substantial enhancement in the bioavailability of both drugs following transferosomal patch application. Regarding sustained drug release, RSM concentrations remained above the limit of quantification (LOQ) for 24 hours, while RTG concentrations persisted above LOQ for 36 hours. After these respective time points, drug concentrations in plasma fell below the limit of detection (LOD). This observation indicates that the formulated patches have RSM for up to 24 hours and RTG for up to 36 hours with significant quantities.\u003c/p\u003e \u003cp\u003eIn summation, the comparative analysis of the obtained data against reference data suggests that the transferosomal patch not only substantially enhances the bioavailability of both drugs but also achieves controlled and sustained drug release into plasma over a 24-hour duration.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab5\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 5\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eComparison of actual pharmacokinetic parameters with reported values\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\"\u0026plusmn;\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\"\u0026plusmn;\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\"\u0026plusmn;\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePharmacokinetic Parameters\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eReported (RM -NPs IV)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eActual\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eReported (Neupro)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eActual\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eC \u003csub\u003emax\u003c/sub\u003e (ng. ml)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c2\"\u003e \u003cp\u003e97 .34\u0026thinsp;\u0026plusmn;\u0026thinsp;5.10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e199.3\u0026thinsp;\u0026plusmn;\u0026thinsp;6.01\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9.83\u0026thinsp;\u0026plusmn;\u0026thinsp;2.80\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c5\"\u003e \u003cp\u003e107.6\u0026thinsp;\u0026plusmn;\u0026thinsp;1.17\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eT\u003csub\u003emax\u003c/sub\u003e (h)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c2\"\u003e \u003cp\u003e0.5\u0026thinsp;\u0026plusmn;\u0026thinsp;0.02\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e12\u0026thinsp;\u0026plusmn;\u0026thinsp;0.019\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7.33\u0026thinsp;\u0026plusmn;\u0026thinsp;2.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c5\"\u003e \u003cp\u003e18\u0026thinsp;\u0026plusmn;\u0026thinsp;3.24\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eT\u003csub\u003e1/2\u003c/sub\u003e(h)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c2\"\u003e \u003cp\u003e2.68\u0026thinsp;\u0026plusmn;\u0026thinsp;0.95\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e18.1350\u0026thinsp;\u0026plusmn;\u0026thinsp;3.13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e22.35\u0026thinsp;\u0026plusmn;\u0026thinsp;12.83\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c5\"\u003e \u003cp\u003e33.44\u0026thinsp;\u0026plusmn;\u0026thinsp;1.10\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAUC(mg \u0026sdot; h/ml)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c2\"\u003e \u003cp\u003e388.41\u0026thinsp;\u0026plusmn;\u0026thinsp;19.75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e2403.24\u0026thinsp;\u0026plusmn;\u0026thinsp;7.11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e169.39\u0026thinsp;\u0026plusmn;\u0026thinsp;30.77\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c5\"\u003e \u003cp\u003e2253.655\u0026thinsp;\u0026plusmn;\u0026thinsp;2.15\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMRT(h)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c2\"\u003e \u003cp\u003e3.94\u0026thinsp;\u0026plusmn;\u0026thinsp;0.83\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e7.5\u0026thinsp;\u0026plusmn;\u0026thinsp;1.51\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c5\"\u003e \u003cp\u003e10.09\u0026thinsp;\u0026plusmn;\u0026thinsp;4.02\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec34\" class=\"Section3\"\u003e \u003ch2\u003e4.2.11 Stability Study of Formulation\u003c/h2\u003e \u003cp\u003eStability studies of the formulation were conducted under distinct environmental conditions to rigorously evaluate its robustness. Parameters including % \u003cem\u003ein vitro\u003c/em\u003e drug release, % drug content, tensile strength, and FTIR were systematically assessed at predefined intervals, specifically at days 0, 30, 60, and 90. The outcome of the stability studies unequivocally affirms the physical and chemical stability of the formulation. Comprehensive results, as depicted in Table\u0026nbsp;\u003cspan refid=\"Tab6\" class=\"InternalRef\"\u003e6\u003c/span\u003e and illustrated in Fig.\u0026nbsp;\u003cspan refid=\"Fig11\" class=\"InternalRef\"\u003e11\u003c/span\u003e \u003cb\u003eand\u003c/b\u003e Fig.\u0026nbsp;\u003cspan refid=\"Fig12\" class=\"InternalRef\"\u003e12\u003c/span\u003e, provide a detailed overview of the formulation's stability performance over the designated time points.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab6\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 6\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eResults of stability studies\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"7\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eTime\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eSpecifications\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e% \u003cem\u003eIn-Vitro\u003c/em\u003e drug release\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e% Drug Content\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eTensile strength\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eRTG\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRSM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eRTG\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eRSM\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eDay 0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e93\u0026thinsp;\u0026plusmn;\u0026thinsp;0.6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e91.82\u0026thinsp;\u0026plusmn;\u0026thinsp;0.29\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e98.3\u0026thinsp;\u0026plusmn;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e99.06\u0026thinsp;\u0026plusmn;\u0026thinsp;0.007\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e124.81\u0026thinsp;\u0026plusmn;\u0026thinsp;0.005\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e40\u0026thinsp;\u0026plusmn;\u0026thinsp;2\u0026deg;C,\u003c/p\u003e \u003cp\u003e75\u0026thinsp;\u0026plusmn;\u0026thinsp;5% RH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e93.24\u0026thinsp;\u0026plusmn;\u0026thinsp;0.6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e91.21\u0026thinsp;\u0026plusmn;\u0026thinsp;0.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e98.02\u0026thinsp;\u0026plusmn;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e99\u0026thinsp;\u0026plusmn;\u0026thinsp;0.0073\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e124.75\u0026thinsp;\u0026plusmn;\u0026thinsp;0.005\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eDay 30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e93.1\u0026thinsp;\u0026plusmn;\u0026thinsp;0.74\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e90.77\u0026thinsp;\u0026plusmn;\u0026thinsp;0.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e97.81\u0026thinsp;\u0026plusmn;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e98.69\u0026thinsp;\u0026plusmn;\u0026thinsp;0.004\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e125.08\u0026thinsp;\u0026plusmn;\u0026thinsp;0.0024\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e40\u0026thinsp;\u0026plusmn;\u0026thinsp;2\u0026deg;C,\u003c/p\u003e \u003cp\u003e75\u0026thinsp;\u0026plusmn;\u0026thinsp;5% RH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e93.41\u0026thinsp;\u0026plusmn;\u0026thinsp;0.7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e90.83\u0026thinsp;\u0026plusmn;\u0026thinsp;0.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e97.52\u0026thinsp;\u0026plusmn;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e98.77\u0026thinsp;\u0026plusmn;\u0026thinsp;0.004\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e125.13\u0026thinsp;\u0026plusmn;\u0026thinsp;0.0024\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eDay 60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e92.7\u0026thinsp;\u0026plusmn;\u0026thinsp;0.19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e90.52\u0026thinsp;\u0026plusmn;\u0026thinsp;0.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e98.01\u0026thinsp;\u0026plusmn;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e98.9\u0026thinsp;\u0026plusmn;\u0026thinsp;0.0013\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e125.11\u0026thinsp;\u0026plusmn;\u0026thinsp;0.00181\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e40\u0026thinsp;\u0026plusmn;\u0026thinsp;2\u0026deg;C,\u003c/p\u003e \u003cp\u003e75\u0026thinsp;\u0026plusmn;\u0026thinsp;5% RH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e92.81\u0026thinsp;\u0026plusmn;\u0026thinsp;0.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e90.85\u0026thinsp;\u0026plusmn;\u0026thinsp;0.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e98.05\u0026thinsp;\u0026plusmn;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e98.6\u0026thinsp;\u0026plusmn;\u0026thinsp;0.0013\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e124.51\u0026thinsp;\u0026plusmn;\u0026thinsp;0.00181\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eDay 90\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e92.1\u0026thinsp;\u0026plusmn;\u0026thinsp;0.75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e90.68\u0026thinsp;\u0026plusmn;\u0026thinsp;0.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e98.03\u0026thinsp;\u0026plusmn;\u0026thinsp;0.004\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e98.57\u0026thinsp;\u0026plusmn;\u0026thinsp;0.002\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e125.45\u0026thinsp;\u0026plusmn;\u0026thinsp;0.0061\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e40\u0026thinsp;\u0026plusmn;\u0026thinsp;2\u0026deg;C,\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e75\u0026thinsp;\u0026plusmn;\u0026thinsp;5% RH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e92.01\u0026thinsp;\u0026plusmn;\u0026thinsp;0.7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e90.79\u0026thinsp;\u0026plusmn;\u0026thinsp;0.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e98.01\u0026thinsp;\u0026plusmn;\u0026thinsp;0.004\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e98.83\u0026thinsp;\u0026plusmn;\u0026thinsp;0.002\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e125.05\u0026thinsp;\u0026plusmn;\u0026thinsp;0.0061\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003c/div\u003e"},{"header":"5 Conclusion","content":"\u003cp\u003eIn this study, we set out to address the pressing need for improved treatment options for Parkinson's disease, given the significant and projected increase in cases by 2040. The main goal of our study was to create transferosome patches that held two drugs from two different Biopharmaceutics Classification System (BCS) classes: RTG (BCS class II) and RSM (BCS class III). These patches were rigorously evaluated using a comprehensive set of parameters. The results obtained from this investigation are promising. The transferosomal patches exhibited favorable characteristics, including good tensile strength and controlled drug release, which are essential for an effective drug delivery system. Moreover, the pharmacokinetic studies revealed a rapid onset of action, which is particularly valuable for a condition like PD, where quick relief can significantly improve the patient's quality of life. Additionally, the in vivo skin irritancy studies indicated that the application of these patches did not cause any damage to the local tissue, demonstrating their safety. While the results of this study indicate the potential of the prepared transferosomal patches in Parkinson's disease treatment, it is important to acknowledge the typographical error in the abstract's conclusion. The study has shown potential for Parkinson's disease treatment rather than Alzheimer's. The research on transferosome patches for Parkinson's disease holds significant promise for advancing drug delivery in this field and addressing neurodegenerative disorders. The success of these patches in the study encourages further investigations and improvements. This includes the imperative transition from preclinical evaluations to rigorous clinical trials, shedding light on the effectiveness and safety of transferosome patches in human patients. Continuous optimization of patch formulations can lead to even more effective drug delivery systems, with potential refinements in drug release profiles and therapeutic outcomes. Exploring combination therapies by incorporating other therapeutic agents alongside RTG and RSM within the transferosome patches offers the potential for more comprehensive treatment strategies. Additionally, assessing the long-term efficacy and durability of these patches is essential to confirming their sustained benefits in managing Parkinson's disease symptoms. Personalized medicine approaches, involving the customization of patch compositions to individual patient profiles, could lead to more targeted and effective therapies. Comparative studies against existing treatments, including medications and surgical interventions, will help provide a comprehensive assessment of the advantages and limitations of the transferosome patch approach. This research sets the stage for a dynamic and transformative future in Parkinson's disease treatment and drug delivery. In conclusion, this research paves the way for the development of innovative and patient-centric treatment options for Parkinson's disease. The successful formulation and evaluation of transferosome patches offer a promising avenue for future research and clinical translation, potentially revolutionizing the management of this debilitating condition.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgment\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors are thankful to Neuland Laboratory Limited, Mumbai, India for providing Retigabine HCl as a gift sample. The authors are also thankful to Dr. Guno Chakraborty and Dr. Snigdha Mandal Das for guiding in animal studies. Additionally, the authors are thankful to the management of Parul University for providing the infrastructure requirement for the research.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eEthics approval\u003cstrong\u003e\u0026nbsp;was done by the\u0026nbsp;\u003c/strong\u003eInstitutional Animal Ethical Committee at Parul Institute of Pharmacy and Research, India, bearing reference no. \u003cstrong\u003ePIPR 984/2022/02/17.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot Applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot Applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026apos; contributions\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"642\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"10.280373831775702%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eSr. No.\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.69158878504673%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eName of Author\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"71.02803738317758%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eRole(s) of Author\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"10.280373831775702%\" valign=\"top\"\u003e\n \u003cp\u003e01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.69158878504673%\" valign=\"top\"\u003e\n \u003cp\u003eShivani Patel\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"71.02803738317758%\" valign=\"top\"\u003e\n \u003cp\u003eConcept, Data compilation, Interpretation, Writing - Original Draft\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"10.280373831775702%\" valign=\"top\"\u003e\n \u003cp\u003e02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.69158878504673%\" valign=\"top\"\u003e\n \u003cp\u003eLalit Lata Jha\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"71.02803738317758%\" valign=\"top\"\u003e\n \u003cp\u003eSupervision, Writing - Review \u0026amp; Editing\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"10.280373831775702%\" valign=\"top\"\u003e\n \u003cp\u003e03\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.69158878504673%\" valign=\"top\"\u003e\n \u003cp\u003eRiya Patel\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"71.02803738317758%\" valign=\"top\"\u003e\n \u003cp\u003eWriting \u0026amp; Editing\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n"},{"header":"References","content":"\u003col\u003e\n \u003cli\u003eTorpy JM, Lynm C, Glass RM. Parkinson Disease [Internet]. JAMA. 2004 [cited 2023 Oct 12]. p. 390. Available from: https://www.who.int/news-room/fact-sheets/detail/parkinson-disease\u003c/li\u003e\n \u003cli\u003eBloem BR, Okun MS, Klein C. Parkinson\u0026rsquo;s disease. The Lancet. 2021;397:2284\u0026ndash;303. \u003c/li\u003e\n \u003cli\u003eDe Caro V, Giandalia G, Siragusa MG, Sutera FM, Giannola LI. New prospective in treatment of Parkinson\u0026rsquo;s disease: Studies on permeation of ropinirole through buccal mucosa. Int J Pharm. 2012;429:78\u0026ndash;83. \u003c/li\u003e\n \u003cli\u003eOf D, Accurate AN, Spectroscopic U V, For M, In T, Buffers V. SHORT COMMUNICATIONS DEVELOPMENT OF AN ACCURATE UV SPECTROSCOPIC METHOD FOR TINIDAZOLE IN VAGINAL BUFFERS. 2024;61:64\u0026ndash;7. \u003c/li\u003e\n \u003cli\u003eAung TY, Soo S. Drugs Induced Nausea and Vomiting: an Overview. IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS. 11:5\u0026ndash;09. \u003c/li\u003e\n \u003cli\u003eElshoff JP, Cawello W, Andreas JO, Mathy FX, Braun M. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson\u0026rsquo;s disease and restless legs syndrome. Drugs. 2015;75:487\u0026ndash;501. \u003c/li\u003e\n \u003cli\u003eLecht S, Haroutiunian S, Hoffman A, Lazarovici P. Therapeutics and Clinical Risk Management ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/dtcr20 Rasagiline-a novel MAO B inhibitor in Parkinson\u0026rsquo;s disease therapy. 2007; \u003c/li\u003e\n \u003cli\u003eShehab-ElDin AN, Sobh RA, Rabie AM, Mohamed WS, Nasr HE. Polyamide 6/tallow modified clay nanofibrous mat coupled with hydrogels for potential topical/transdermal delivery of doxycycline hydrochloride. J Pharm Investig. 2023;53:307\u0026ndash;21. \u003c/li\u003e\n \u003cli\u003ePatel G, Patel P, Sonara Z, Patel R, Pharm ( M. Fabrication and Optimization of 3D Printed Insert Coated With Rate Controlling Membrane in the Treatment of Recurrent Vaginal Candidiasis Via Vaginal Route. [cited 2023 Aug 24]; Available from: https://ssrn.com/abstract=4514316\u003c/li\u003e\n \u003cli\u003ePatel R, Shah U, Patel G. Optimization of poly(\u0026Epsilon;-caprolactone) based biodegradable in situ porous drug-eluting insert of BCS class II/IV drug for targeted application. International Journal of Polymeric Materials and Polymeric Biomaterials [Internet]. 2024 [cited 2023 Jul 18];73:885\u0026ndash;96. Available from: https://www.tandfonline.com/doi/abs/10.1080/00914037.2023.2222334\u003c/li\u003e\n \u003cli\u003eshah S, Patel R, Patel G. Nanocomposite hydrogels: an optimistic insight towards the treatments of ocular disorders. Recent Pat Nanotechnol [Internet]. 2023 [cited 2023 Aug 24];17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/37519202\u003c/li\u003e\n \u003cli\u003eShah S, Patel AA, Prajapati BG, Alexander A, Pandya V, Trivedi N, et al. Multifaceted nanolipidic carriers: a modish stratagem accentuating nose-to-brain drug delivery [Internet]. Journal of Nanoparticle Research. Springer; 2023 [cited 2023 Aug 24]. p. 1\u0026ndash;34. Available from: https://link.springer.com/article/10.1007/s11051-023-05804-4\u003c/li\u003e\n \u003cli\u003ePatel R, Yadav BK, Patel G. Progresses in Nano-Enabled Platforms for the Treatment of Vaginal Disorders. Recent Pat Nanotechnol [Internet]. 2022 [cited 2023 May 18];17:208\u0026ndash;27. Available from: https://pubmed.ncbi.nlm.nih.gov/35762539/\u003c/li\u003e\n \u003cli\u003ePatel R, Patel G. Preparation and Characterization of a Novel Optimum Modified Liquisolid Compact to Enhance the Dissolution Profile of Mifepristone. Dissolut Technol. 2023;30:238\u0026ndash;44. \u003c/li\u003e\n \u003cli\u003ePatel R, Patel S, Momin I, Shah S. The Evolving Landscape of Colonoscopy: Recent Developments and Complication Management. Colonoscopy - Diagnostic and Therapeutic Advances [Internet]. 2024 [cited 2024 Mar 28]; Available from: undefined/chapters/1160312\u003c/li\u003e\n \u003cli\u003eTrivedi S, Shah S, Patel R. Review on novel oral iron formulations with enhanced bioavailability for the treatment of iron deficiency. J Drug Deliv Sci Technol. 2023;90:105181. \u003c/li\u003e\n \u003cli\u003eSong JG, Lee SH, Han HK. Organic clay-based fast dissolving microneedles for efficient transdermal delivery of therapeutic proteins. J Pharm Investig. 2024;1\u0026ndash;12. \u003c/li\u003e\n \u003cli\u003eOpatha SAT, Titapiwatanakun V, Chutoprapat R. Transfersomes: A promising nanoencapsulation technique for transdermal drug delivery. Pharmaceutics. 2020;12:1\u0026ndash;23. \u003c/li\u003e\n \u003cli\u003ePatel R, Yadav BK, Patel G. Progresses in Nano-Enabled Platforms for the Treatment of Vaginal Disorders. Recent Pat Nanotechnol. 2022;17:208\u0026ndash;27. \u003c/li\u003e\n \u003cli\u003eShah S, Patel AA, Prajapati BG, Alexander A, Pandya V, Trivedi N, et al. Multifaceted nanolipidic carriers: a modish stratagem accentuating nose-to-brain drug delivery. Journal of Nanoparticle Research. Springer; 2023. p. 1\u0026ndash;34. \u003c/li\u003e\n \u003cli\u003ePatel RJ, Pandey P, Patel AA, Prajapati BG, Alexander A, Pandya V, et al. Ordered mesoporous silica nanocarriers: An innovative paradigm and a promising therapeutic efficient carrier for delivery of drugs. J Drug Deliv Sci Technol. Elsevier; 2023. p. 104306. \u003c/li\u003e\n \u003cli\u003eshah S, Patel R, Patel G. Nanocomposite hydrogels: an optimistic insight towards the treatments of ocular disorders. Recent Pat Nanotechnol. 2023;17. \u003c/li\u003e\n \u003cli\u003eSahu BP, Baishya R, Hatiboruah JL, Laloo D, Biswas N. A comprehensive review on different approaches for tumor targeting using nanocarriers and recent developments with special focus on multifunctional approaches. Journal of Pharmaceutical Investigation 2022 52:5. 2022;52:539\u0026ndash;85. \u003c/li\u003e\n \u003cli\u003eElmowafy M, Al-Sanea MM. Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies. Saudi Pharmaceutical Journal. 2021;29:999\u0026ndash;1012. \u003c/li\u003e\n \u003cli\u003ePatel S, Jha LL. Application of Plackett-Burman and Box-Behnken Designs for Screening and Optimization of Rotigotine Hcl and Rasagiline Mesylate Transfersomes: a Statistical Approach. International Journal of Applied Pharmaceutics. 2023;15:238\u0026ndash;45. \u003c/li\u003e\n \u003cli\u003eEckertov\u0026aacute; L. Thin Film Thickness and Deposition Rate Measurement Methods. Physics of Thin Films. 1977;52\u0026ndash;71. \u003c/li\u003e\n \u003cli\u003eSolutions POF, Of D, Valid M. Stage 6 Harmonization Official. 2012;08:1\u0026ndash;5. \u003c/li\u003e\n \u003cli\u003eVaria U, Joshi D, Jadeja M, Katariya H, Detholia K, Soni V. Development and evaluation of ultradeformable vesicles loaded transdermal film of boswellic acid. Futur J Pharm Sci [Internet]. 2022 [cited 2023 Aug 24];8:1\u0026ndash;16. Available from: https://fjps.springeropen.com/articles/10.1186/s43094-022-00428-2\u003c/li\u003e\n \u003cli\u003eKathpalia H, Patil A. Formulation and evaluation of orally disintegrating films of levocetirizine dihydrochloride. Indian J Pharm Sci. 2017;79:204\u0026ndash;11. \u003c/li\u003e\n \u003cli\u003eSpeer I, Preis M, Breitkreutz J. Dissolution testing of oral film preparations: Experimental comparison of compendial and non-compendial methods. Int J Pharm. 2019;561:124\u0026ndash;34. \u003c/li\u003e\n \u003cli\u003ePatel SM, Jha LL. Simultaneous Uv Method Development for Determination of Rotigotine Hydrochloride and Rasagiline Mesylate. Indian Drugs. 2023;60:73\u0026ndash;9. \u003c/li\u003e\n \u003cli\u003eHwang SJ, Lee JH, Choi JH, Oh GS, So HS, Park JB, et al. Development of a self-microemulsifying drug delivery system using a Dunnione to enhance bioavailability. J Pharm Investig. 2024;1\u0026ndash;11. \u003c/li\u003e\n \u003cli\u003ePatel R, Shah R, Patel A, Hadiya K, Parmar J, Patel G. Off-Label use of Raloxifene hydrochloride in uterine fibroids: A novel insert-based formulation approach and IN-VIVO preclinical evaluation. J Drug Deliv Sci Technol. 2023;84:104552. \u003c/li\u003e\n \u003cli\u003eHinkelmann K. Design and Analysis of Experiments. Design and Analysis of Experiments. 2012;3:1\u0026ndash;566. \u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Rotigotine HCL, Rasagiline mesylate, Transferosomes Patches, Parkinson's Disease, Combination therapy","lastPublishedDoi":"10.21203/rs.3.rs-4761605/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4761605/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eParkinson\u0026rsquo;s disease (PD) is a clinical syndrome with symptoms like rest tremor, rigidity, bradykinesia, instability of posture, and a diversity of other motor and non-motor symptoms. The disease study prognosis is that the number of PD cases will double from 7\u0026nbsp;million in 2015 to 13\u0026nbsp;million in 2040. The majority of the treatments for PD include surgery and medications. The drawback of available treatments is that they are invasive and lead to systemic side effects.\u003c/p\u003e\u003ch2\u003eAim\u003c/h2\u003e \u003cp\u003eThis research aims to prepare transferosome patches of both drugs of different BCS classes, Rotigotine HCL (RTG) BCS class II and Rasagiline mesylate (RSM) BCS class III, and evaluate them with different parameters to check the synergistic effects of both drugs with the in vivo study.\u003c/p\u003e\u003ch2\u003eMethod\u003c/h2\u003e \u003cp\u003eA transferosomal patch of drugs was prepared by thin film hydration followed by a homogenization casting method. The patches were optimized with the central composite design. The optimized batch was further evaluated with various parameters like thickness, folding endurance, drug content, in vitro drug release, ex vivo drug permeation, pharmacokinetics, and in vivo skin irritancy studies.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eAfter the evaluation of the drugs, loaded transferosome patches show good tensile strength; drug content was found within the range in both cases and shows the controlled release of the drugs; pharmacokinetic studies show the quick onset of action; and in vivo, skin irritancy results show no damage to the tissue at the site of action.\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eFrom the results, it has been observed that the prepared transferosome patch can treat PD with the synergistic effects of the drugs via the topical route.\u003c/p\u003e","manuscriptTitle":"Transferosomal Formulation of Rotigotine Hcl and Rasagiline Mesylate: a Step Towards Minimally Invasive Parkinson's Disease Therapy","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-10-15 07:28:19","doi":"10.21203/rs.3.rs-4761605/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"e20a6fe3-65c9-43f8-8546-6c57e5afad85","owner":[],"postedDate":"October 15th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2024-10-15T07:36:22+00:00","versionOfRecord":[],"versionCreatedAt":"2024-10-15 07:28:19","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4761605","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4761605","identity":"rs-4761605","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}